Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
ABAT	GABAT	ENSG00000183044	4-aminobutyrate aminotransferase	16	8674565-8784575	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041528, HPA041690	Enhanced	Supported	Supported	Mitochondria	Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 164.5;kidney: 135.3;liver: 175.2	thyroid gland: 47.5	Cell line enhanced		Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
ABCA1	ABC1, HDLDT1, TGD	ENSG00000165029	ATP binding cassette subfamily A member 1	9	104781002-104928237	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA057283, CAB069889	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			adrenal gland: 38.0	Cell line enhanced		U-87 MG: 76.7
ABCC1	GS-X, MRP, MRP1	ENSG00000103222	ATP binding cassette subfamily C member 1	16	15949577-16143074	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002380	Uncertain		Supported	Plasma membrane	Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 18.6	Cell line enhanced		EFO-21: 84.1
ABCC2	CMOAT, cMRP, DJS, MRP2	ENSG00000023839	ATP binding cassette subfamily C member 2	10	99782732-99852192	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004860, CAB037271	Enhanced				Renal cancer:1.93e-5 (unfavourable)	Tissue enhanced	Group enriched	10	duodenum: 43.5;gallbladder: 42.7;kidney: 20.9;liver: 67.6;small intestine: 49.5	breast: 4.4	Cell line enhanced		A549: 203.8;Hep G2: 155.8
ABCC8	ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2	ENSG00000006071	ATP binding cassette subfamily C member 8	11	17392885-17476845	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB011451, HPA042318	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 11.3	adrenal gland: 7.5	Cell line enhanced		A549: 1.7;AN3-CA: 1.8;SCLC-21H: 9.0
ABL1	ABL, c-ABL, JTK7, p150	ENSG00000097007	ABL proto-oncogene 1, non-receptor tyrosine kinase	9	130713946-130887675	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002686, HPA027251, HPA027280, HPA028409	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 83.9	Expressed in all		
ACAA1		ENSG00000060971	Acetyl-CoA acyltransferase 1	3	38103129-38137242	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006764, HPA007244	Enhanced		Enhanced	Peroxisomes	Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable)	Expressed in all	Expressed in all			liver: 328.4	Expressed in all		
ACE	ACE1, CD143, DCP1	ENSG00000159640	Angiotensin I converting enzyme	17	63477061-63498380	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002426, CAB002921, HPA029298, HPA069790	Enhanced		Approved	Vesicles		Expressed in all	Tissue enhanced		duodenum: 178.9;small intestine: 291.6	testis: 83.7	Cell line enhanced		ASC TERT1: 44.4;HUVEC TERT2: 28.2
ACE2		ENSG00000130234	Angiotensin I converting enzyme 2	X	15561033-15602148	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA000288, CAB026174	Enhanced				Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable)	Tissue enhanced	Group enriched	5	duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0	heart muscle: 27.9	Cell line enhanced		HaCaT: 1.1
ACHE	YT	ENSG00000087085	Acetylcholinesterase (Cartwright blood group)	7	100889994-100896974	Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019704, HPA027098			Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 58.5	cerebral cortex: 14.1	Cell line enhanced		BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
ADA		ENSG00000196839	Adenosine deaminase	20	44619522-44652233	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001399, CAB004307, HPA023884	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.94e-14 (unfavourable), Endometrial cancer:1.23e-7 (unfavourable), Liver cancer:6.77e-5 (unfavourable), Lung cancer:2.20e-4 (unfavourable)	Expressed in all	Tissue enriched	13	duodenum: 487.7	lymph node: 36.5	Cell line enriched	9	MOLT-4: 1479.5
ADH1A	ADH1	ENSG00000187758	Alcohol dehydrogenase 1A (class I), alpha polypeptide	4	99276367-99291028	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009562, HPA047814, HPA060902	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:2.38e-4 (favourable)	Tissue enriched	Tissue enriched	135	liver: 1367.7	gallbladder: 10.1	Cell line enhanced		ASC diff: 3.7
ADH1B	ADH2	ENSG00000196616	Alcohol dehydrogenase 1B (class I), beta polypeptide	4	99304964-99352760	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047814, HPA060902	Supported		Approved	Plasma membrane<br>Cytosol	Renal cancer:7.87e-4 (unfavourable)	Tissue enriched	Group enriched	6	adipose tissue: 1624.6;liver: 3000.2	lung: 388.5	Cell line enriched	7	ASC diff: 4511.9
ADH1C	ADH3	ENSG00000248144	Alcohol dehydrogenase 1C (class I), gamma polypeptide	4	99336492-99353027	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047814, HPA060902	Supported		Supported	Plasma membrane<br>Cytosol	Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 508.1;liver: 888.0;stomach: 477.4	colon: 276.3	Cell line enhanced		ASC TERT1: 2.5;HSkMC: 7.7
ADK	AK	ENSG00000156110	Adenosine kinase	10	74151185-74709303	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB032876, HPA038391, HPA038409	Approved		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:1.93e-4 (unfavourable), Liver cancer:9.91e-4 (favourable)	Expressed in all	Expressed in all			liver: 77.6	Expressed in all		
ADORA1	RDC7	ENSG00000163485	Adenosine A1 receptor	1	203090654-203167405	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044383			Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 50.2;testis: 25.4	parathyroid gland: 18.9	Cell line enhanced		CACO-2: 33.2;RH-30: 62.4;RPTEC TERT1: 23.7;SK-BR-3: 26.3
ADORA2A	ADORA2, RDC8	ENSG00000128271	Adenosine A2a receptor	22	24417879-24442360	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001943, HPA065566, HPA075997	Enhanced	Supported				Not detected	Tissue enhanced		bone marrow: 24.6;lymph node: 22.7	appendix: 17.8	Cell line enhanced		Karpas-707: 36.8;SK-BR-3: 55.0;U-266/70: 38.8;U-266/84: 50.0;U-698: 37.2
ADORA2B		ENSG00000170425	Adenosine A2b receptor	17	15944917-15975746	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA073747			Uncertain	Cytosol		Mixed	Mixed			colon: 8.5	Cell line enhanced		HMC-1: 142.9
ADORA3	AD026	ENSG00000282608	Adenosine A3 receptor	1	111499429-111503760	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level								Mixed			adrenal gland: 18.4	Cell line enriched	12	HMC-1: 89.3
ADRA1A	ADRA1C, ADRA1L1	ENSG00000120907	Adrenoceptor alpha 1A	8	26748150-26867273	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029678, HPA029679	Approved					Tissue enhanced	Tissue enhanced		adipose tissue: 22.6;liver: 31.6;prostate: 20.8	seminal vesicle: 19.1	Not detected		
ADRA1B		ENSG00000170214	Adrenoceptor alpha 1B	5	159916783-159972544	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA074416			Supported	Plasma membrane	Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 14.8;spleen: 17.0	ovary: 4.8	Cell line enhanced		EFO-21: 12.8;TIME: 10.9;U-2 OS: 9.6
ADRA1D	ADRA1, ADRA1A, ADRA1R	ENSG00000171873	Adrenoceptor alpha 1D	20	4220631-4249074	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA038789	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 4.3;prostate: 4.5	seminal vesicle: 2.6	Cell line enhanced		BJ: 6.7;CAPAN-2: 3.1;fHDF/TERT166: 3.7
ADRA2A	ADRA2, ADRA2R, ADRAR	ENSG00000150594	Adrenoceptor alpha 2A	10	111077163-111080907	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:8.06e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 33.2	Cell line enhanced		ASC diff: 7.4;ASC TERT1: 9.3;HEL: 18.7;HeLa: 7.4;HSkMC: 23.3
ADRA2C	ADRA2L2, ADRA2RL2, ADRARL2	ENSG00000184160	Adrenoceptor alpha 2C	4	3766348-3768526	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057688	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 20.9;endometrium: 26.0;seminal vesicle: 26.8	fallopian tube: 7.9	Cell line enhanced		Hep G2: 9.0;MCF7: 16.8;SCLC-21H: 9.5;SH-SY5Y: 10.3
ADRB1	ADRB1R	ENSG00000043591	Adrenoceptor beta 1	10	114044056-114046908	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067972	Enhanced					Tissue enriched	Tissue enhanced		placenta: 45.4	heart muscle: 10.8	Cell line enhanced		HDLM-2: 6.7;THP-1: 3.2;TIME: 5.0
ADRB2	ADRB2R, ADRBR, B2AR, BAR	ENSG00000169252	Adrenoceptor beta 2	5	148825245-148828687	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003431, HPA075322	Uncertain		Uncertain	Cytosol	Renal cancer:3.15e-9 (favourable)	Mixed	Mixed			lung: 16.3	Cell line enhanced		hTCEpi: 28.8;hTERT-HME1: 31.6
ADRB3		ENSG00000188778	Adrenoceptor beta 3	8	37962991-37966965	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA061969	Uncertain					Not detected	Tissue enhanced		ovary: 8.9;placenta: 3.7	gallbladder: 2.2	Not detected		
AGTR1	AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R	ENSG00000144891	Angiotensin II receptor type 1	3	148697784-148743008	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003596	Enhanced		Uncertain	Vesicles		Group enriched	Tissue enhanced		placenta: 214.0	liver: 50.9	Cell line enhanced		ASC diff: 127.9;BJ hTERT+ SV40 Large T+: 33.9;HBF TERT88: 54.9;HSkMC: 24.7
AKR1C2	BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD	ENSG00000151632	Aldo-keto reductase family 1 member C2	10	4987400-5018031	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB047304, HPA068265	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Group enriched	Group enriched	5	adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0	duodenum: 29.8	Cell line enhanced		A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
AKR1D1	SRD5B1	ENSG00000122787	Aldo-keto reductase family 1 member D1	7	138002324-138117986	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057002	Enhanced		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.91e-5 (favourable)	Tissue enriched	Tissue enriched	31	liver: 229.4	breast: 7.2	Cell line enriched	16	Hep G2: 8.6
ALAD	ALADH, PBGS	ENSG00000148218	Aminolevulinate dehydratase	9	113386317-113401333	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021023, HPA022124	Enhanced				Colorectal cancer:7.33e-5 (unfavourable), Liver cancer:8.80e-5 (favourable), Renal cancer:1.65e-4 (favourable), Endometrial cancer:5.64e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 147.1	Expressed in all		
ALDH2		ENSG00000111275	Aldehyde dehydrogenase 2 family (mitochondrial)	12	111766887-111817529	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051065	Approved				Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 441.5	Cell line enhanced		HHSteC: 81.5;SK-BR-3: 150.4
ALK	CD246	ENSG00000171094	Anaplastic lymphoma receptor tyrosine kinase	2	29192774-29921566	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010694	Approved		Supported	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 2.7;testis: 2.0	adrenal gland: 0.5	Cell line enriched	6	SH-SY5Y: 28.3
ALOX5	5-LOX	ENSG00000012779	Arachidonate 5-lipoxygenase	10	45374176-45446119	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071285	Enhanced		Supported	Nucleoplasm	Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 41.3	bone marrow: 28.8	Cell line enhanced		BEWO: 10.4;Daudi: 22.8;HMC-1: 20.7;RT4: 14.0;U-266/70: 11.3
ALPPL2		ENSG00000163286	Alkaline phosphatase, placental like 2	2	232406843-232410714	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB020698, HPA038764, HPA038765, HPA051699	Supported		Approved	Plasma membrane		Tissue enhanced	Tissue enhanced		fallopian tube: 1.5	lung: 0.7	Group enriched	29	BEWO: 6.5;CAPAN-2: 29.9;HaCaT: 22.2
AMY2A	AMY2	ENSG00000243480	Amylase, alpha 2A (pancreatic)	1	103616811-103625780	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, CAB045960, HPA046980	Enhanced					Tissue enriched	Tissue enriched	313	pancreas: 31329.4	ovary: 99.9	Not detected		
ANO1	DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A	ENSG00000131620	Anoctamin 1	11	70078302-70189528	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032148, HPA057356	Enhanced				Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 220.9;seminal vesicle: 298.5	skin: 115.8	Group enriched	5	A-431: 121.8;CAPAN-2: 182.7;HaCaT: 224.5
ANXA1	ANX1, LPC1	ENSG00000135046	Annexin A1	9	73151757-73170393	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA011271, HPA011272, CAB013023, CAB035987, CAB058693	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable)	Expressed in all	Tissue enriched	6	esophagus: 7548.8	tonsil: 1217.6	Mixed		
AOC3	HPAO, VAP-1, VAP1	ENSG00000131471	Amine oxidase, copper containing 3	17	42851184-42858130	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000980, CAB025797	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 450.1	smooth muscle: 205.7	Cell line enriched	17	ASC diff: 210.1
APEX1	APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1	ENSG00000100823	Apurinic/apyrimidinic endodeoxyribonuclease 1	14	20455191-20457772	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000956, HPA002564, CAB004294, CAB047307	Enhanced		Enhanced	Nucleus	Liver cancer:7.82e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 176.5	Expressed in all		
APP	AD1	ENSG00000142192	Amyloid beta precursor protein	21	25880550-26171128	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000157, HPA001462	Enhanced		Approved	Golgi apparatus<br>Vesicles	Renal cancer:2.79e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1203.4	Mixed		
AR	AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1	ENSG00000169083	Androgen receptor	X	67544032-67730619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000001, HPA065701, CAB065764	Enhanced		Approved	Mitochondria	Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable)	Mixed	Mixed			fallopian tube: 42.3	Cell line enhanced		AF22: 15.6;HAP1: 21.1;LHCN-M2: 14.9;RH-30: 28.3
ASIC1	ACCN2, BNaC2, hBNaC2	ENSG00000110881	Acid sensing ion channel subunit 1	12	50057548-50083611	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA058870			Approved	Golgi apparatus<br>Plasma membrane		Tissue enhanced	Tissue enriched	10	cerebral cortex: 56.8	parathyroid gland: 5.7	Cell line enhanced		SH-SY5Y: 30.8
ATIC	AICARFT, IMPCHASE, PURH	ENSG00000138363	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	2	215311817-215349773	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013462, HPA021012	Supported		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 44.8	Expressed in all		
ATP1A1		ENSG00000163399	ATPase Na+/K+ transporting subunit alpha 1	1	116372668-116410261	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB018702, CAB069993	Enhanced				Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 2487.1	Expressed in all		
ATP2C1	ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1	ENSG00000017260	ATPase secretory pathway Ca2+ transporting 1	3	130850595-131016712	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010207, HPA035116, HPA069684	Supported		Enhanced	Golgi apparatus	Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			prostate: 138.3	Expressed in all		
ATP4A	ATP6A	ENSG00000105675	ATPase H+/K+ transporting alpha subunit	19	35550043-35563658	Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039154	Enhanced					Tissue enriched	Tissue enriched	260	stomach: 557.9	pancreas: 2.1	Not detected		
ATP6V1B2	ATP6B2, HO57, VATB, Vma2, VPP3	ENSG00000147416	ATPase H+ transporting V1 subunit B2	8	20197367-20226819	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008147	Enhanced		Supported	Vesicles	Renal cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 304.2	Expressed in all		
AVPR1A	AVPR1	ENSG00000166148	Arginine vasopressin receptor 1A	12	63142759-63150942	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 77.8	adipose tissue: 20.0	Group enriched	8	ASC diff: 3.9;Karpas-707: 9.4;U-266/84: 6.8
AVPR1B	AVPR3	ENSG00000198049	Arginine vasopressin receptor 1B	1	206109692-206117699	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA075404	Supported					Tissue enhanced	Not detected			stomach: 0.3	Not detected		
AVPR2	DIR, DIR3, V2R	ENSG00000126895	Arginine vasopressin receptor 2	X	153902531-153907166	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046678	Approved					Mixed	Tissue enhanced		adipose tissue: 5.8	kidney: 2.8	Cell line enhanced		EFO-21: 3.0;SCLC-21H: 4.6;U-266/84: 2.7;U-698: 2.8
BCHE	CHE1, CHE2, E1	ENSG00000114200	Butyrylcholinesterase	3	165772904-165837472	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001560	Approved				Head and neck cancer:1.06e-4 (unfavourable)	Group enriched	Tissue enhanced		liver: 265.5	endometrium: 67.7	Cell line enriched	7	Karpas-707: 542.1
BCL2	Bcl-2, PPP1R50	ENSG00000171791	BCL2, apoptosis regulator	18	63123346-63320128	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000003, HPA055295	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 69.3	parathyroid gland: 35.3	Cell line enhanced		Karpas-707: 59.5;U-266/70: 217.8
BCR	ALL, BCR1, CML, D22S11, D22S662, PHL	ENSG00000186716	BCR, RhoGEF and GTPase activating protein	22	23179704-23318037	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010421, CAB018545, HPA038337	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.15e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 47.0	Expressed in all		
BDKRB2	BK-2	ENSG00000168398	Bradykinin receptor B2	14	96204679-96244166	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA050841	Approved					Mixed	Mixed			gallbladder: 32.5	Cell line enhanced		ASC TERT1: 34.0;BJ hTERT+: 75.7;U-87 MG: 38.4
BGLAP	OCN	ENSG00000242252	Bone gamma-carboxyglutamate protein	1	156241962-156243321	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			skin: 2.1	Cell line enhanced		U-87 MG: 2.8
BLVRB	FLR, SDR43U1	ENSG00000090013	Biliverdin reductase B	19	40447789-40465840	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041698, HPA041937	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 338.3	Cell line enhanced		A549: 442.0;K-562: 413.4
BRAF	BRAF1	ENSG00000157764	B-Raf proto-oncogene, serine/threonine kinase	7	140719327-140924764	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001328, CAB004552, HPA071048	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
BTK	AGMX1, ATK, IMD1, PSCTK1, XLA	ENSG00000010671	Bruton tyrosine kinase	X	101349447-101390796	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001198, HPA002028, CAB016689	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		lymph node: 65.2;tonsil: 70.8	spleen: 52.7	Cell line enhanced		Daudi: 147.2;HEL: 256.7;HMC-1: 868.2
C1R		ENSG00000159403	Complement C1r	12	7080209-7092607	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001251, HPA001551	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:1.94e-14 (unfavourable)	Expressed in all	Expressed in all			liver: 1226.4	Cell line enhanced		ASC diff: 1273.8;ASC TERT1: 658.4;BJ hTERT+: 685.9;BJ hTERT+ SV40 Large T+ RasG12V: 496.0;HSkMC: 797.4
C1S		ENSG00000182326	Complement C1s	12	6988259-7071032	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016722, HPA018852	Supported		Approved	Nucleus<br>Cytosol	Renal cancer:7.44e-15 (unfavourable), Liver cancer:7.73e-4 (favourable)	Expressed in all	Expressed in all			liver: 1326.7	Cell line enhanced		ASC diff: 521.6;ASC TERT1: 703.0;BJ hTERT+: 271.2;HSkMC: 390.5
C3	ARMD9, C3a, C3b, CPAMD1	ENSG00000125730	Complement C3	19	6677704-6730562	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003563, CAB004209, HPA020432	Enhanced				Renal cancer:1.09e-5 (unfavourable), Liver cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			liver: 2486.8	Group enriched	6	BJ hTERT+: 287.5;EFO-21: 689.2;Hep G2: 539.6;HSkMC: 386.3;SiHa: 220.2
C4A	C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG	ENSG00000244731	Complement C4A (Rodgers blood group)	6	31982024-32002681	Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009811, CAB032603, HPA046356, HPA048287, HPA050103	Approved					Tissue enhanced	Tissue enhanced		liver: 46.1	thyroid gland: 28.2	Group enriched	8	HDLM-2: 49.4;HSkMC: 51.4;U-266/70: 12.8;U-266/84: 23.9
C4B	C4B1, C4B3, C4F, CH, CO4, CPAMD3	ENSG00000224389	Complement C4B (Chido blood group)	6	32014762-32035418	Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046356, HPA048287, HPA050103	Approved					Tissue enhanced	Tissue enhanced		adrenal gland: 59.4;liver: 65.5	fallopian tube,kidney: 18.3	Cell line enriched	5	Karpas-707: 92.1
C5	C5a, C5b, CPAMD4	ENSG00000106804	Complement C5	9	120952335-121050276	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA029339	Uncertain				Liver cancer:9.43e-4 (favourable)	Tissue enriched	Tissue enriched	21	liver: 225.6	lung: 10.5	Cell line enhanced		A549: 25.6;Hep G2: 20.6
CA1	Car1	ENSG00000133742	Carbonic anhydrase 1	8	85327608-85379014	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006558, CAB025790	Enhanced					Group enriched	Group enriched	30	bone marrow: 1216.6;colon: 1022.8;rectum: 2316.0	smooth muscle: 49.9	Cell line enriched	1560	HEL: 1145.7
CA14		ENSG00000118298	Carbonic anhydrase 14	1	150257159-150265078	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008482	Approved		Approved	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 10.6;seminal vesicle: 21.2	skeletal muscle: 9.4	Group enriched	23	AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
CA2	CA-II, CAII, Car2	ENSG00000104267	Carbonic anhydrase 2	8	85463852-85481493	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001550, CAB010102	Enhanced				Renal cancer:5.57e-6 (favourable)	Expressed in all	Tissue enhanced		colon: 604.8;rectum: 627.5;stomach: 918.8	kidney: 308.3	Group enriched	11	HaCaT: 204.1;HEK93: 884.1;THP-1: 278.7
CA3	CAIII, Car3	ENSG00000164879	Carbonic anhydrase 3	8	85373436-85449040	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004967, HPA021775, HPA026700	Enhanced				Breast cancer:4.24e-6 (favourable)	Group enriched	Tissue enriched	13	skeletal muscle: 1838.7	prostate: 138.3	Group enriched	34	HEL: 44.2;RH-30: 77.2
CA4	CAIV, Car4, RP17	ENSG00000167434	Carbonic anhydrase 4	17	60149936-60170899	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011089, HPA017258	Enhanced		Supported	Vesicles		Mixed	Tissue enhanced		colon: 253.5;rectum: 180.9	adipose tissue: 88.7	Not detected		
CA7		ENSG00000168748	Carbonic anhydrase 7	16	66844379-66854153	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047237	Uncertain					Tissue enhanced	Tissue enhanced		colon: 54.6;rectum: 49.8	small intestine: 10.7	Cell line enhanced		REH: 1.0;SCLC-21H: 1.0;THP-1: 1.2
CACNA1A	APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6	ENSG00000141837	Calcium voltage-gated channel subunit alpha1 A	19	13206442-13633025	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA064258, HPA071902	Enhanced		Uncertain	Endoplasmic reticulum	Pancreatic cancer:4.32e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 15.1	stomach: 3.5	Group enriched	7	SCLC-21H: 56.1;U-87 MG: 26.1
CACNA1B	CACNL1A5, CACNN, Cav2.2	ENSG00000148408	Calcium voltage-gated channel subunit alpha1 B	9	137877789-138124624	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA044347	Uncertain					Tissue enhanced	Group enriched	8	adrenal gland: 3.7;cerebral cortex: 14.8;fallopian tube: 4.9;testis: 7.6	prostate: 0.9	Cell line enriched	6	SCLC-21H: 23.0
CACNA1C	CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS	ENSG00000151067	Calcium voltage-gated channel subunit alpha1 C	12	1970786-2697950	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039796, CAB079031	Enhanced	Approved				Mixed	Tissue enhanced		smooth muscle: 30.9	endometrium: 26.2	Cell line enriched	17	HDLM-2: 188.9
CACNA1D	CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2	ENSG00000157388	Calcium voltage-gated channel subunit alpha1 D	3	53328963-53813733	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA020215	Uncertain		Approved	Nuclear membrane	Renal cancer:8.34e-8 (favourable)	Mixed	Mixed			fallopian tube: 13.5	Cell line enhanced		HMC-1: 19.6;RPMI-8226: 38.4;SK-BR-3: 7.4
CACNA1F	AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2	ENSG00000102001	Calcium voltage-gated channel subunit alpha1 F	X	49205063-49233371	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA068379	Supported					Not detected	Mixed			lymph node: 1.6	Cell line enhanced		U-266/70: 1.0
CACNA1G	Cav3.1, NBR13	ENSG00000006283	Calcium voltage-gated channel subunit alpha1 G	17	50561068-50627474	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA004714	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 10.5;cervix, uterine: 8.5	endometrium: 5.2	Cell line enhanced		A549: 8.5;SCLC-21H: 3.3
CACNA1H	Cav3.2	ENSG00000196557	Calcium voltage-gated channel subunit alpha1 H	16	1153121-1221772	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039125	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable)	Expressed in all	Tissue enhanced		ovary: 44.9	seminal vesicle: 39.1	Cell line enhanced		A549: 16.1;AN3-CA: 23.5;MCF7: 36.8;T-47d: 13.0
CACNA1I	Cav3.3	ENSG00000100346	Calcium voltage-gated channel subunit alpha1 I	22	39570753-39689737	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 4.7;thyroid gland: 2.7	adrenal gland: 2.3	Cell line enhanced		SK-BR-3: 1.4;T-47d: 1.0
CACNA1S	CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5	ENSG00000081248	Calcium voltage-gated channel subunit alpha1 S	1	201039512-201112566	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB009507, HPA048892, HPA056815	Enhanced					Tissue enhanced	Tissue enriched	34	skeletal muscle: 103.0	esophagus: 3.0	Group enriched	20	BEWO: 2.0;HSkMC: 1.9
CACNA2D1	CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3	ENSG00000153956	Calcium voltage-gated channel auxiliary subunit alpha2delta 1	7	81946444-82443798	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008213, HPA008621	Enhanced				Renal cancer:1.16e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 35.4	Cell line enhanced		HUVEC TERT2: 45.6;SH-SY5Y: 66.1
CACNA2D2	KIAA0558	ENSG00000007402	Calcium voltage-gated channel auxiliary subunit alpha2delta 2	3	50362799-50504244	FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034771, HPA071829	Enhanced		Approved	Vesicles	Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable)	Tissue enhanced	Tissue enriched	6	lung: 72.9	testis: 12.4	Cell line enriched	8	SH-SY5Y: 201.7
CACNB1	CACNLB1	ENSG00000067191	Calcium voltage-gated channel auxiliary subunit beta 1	17	39173456-39197703	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023343	Approved				Endometrial cancer:3.80e-4 (unfavourable)	Mixed	Group enriched	6	cerebral cortex: 46.7;skeletal muscle: 108.5	skin: 12.3	Mixed		
CACNB2	CACNLB2, MYSB	ENSG00000165995	Calcium voltage-gated channel auxiliary subunit beta 2	10	18140677-18541869	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035325, HPA035326	Uncertain				Renal cancer:3.56e-5 (favourable)	Mixed	Mixed			cerebral cortex: 26.3	Cell line enhanced		HAP1: 8.3;HSkMC: 7.1
CACNB3	CACNLB3	ENSG00000167535	Calcium voltage-gated channel auxiliary subunit beta 3	12	48813794-48828941	FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA059515			Approved	Golgi apparatus<br>Vesicles		Mixed	Mixed			endometrium: 40.0	Cell line enhanced		U-937: 85.2
CACNB4	EJM4	ENSG00000182389	Calcium voltage-gated channel auxiliary subunit beta 4	2	151832768-152099475	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015601	Approved					Mixed	Tissue enhanced		cerebral cortex: 25.9	skin: 8.0	Cell line enhanced		HMC-1: 17.7
CACNG1	CACNLG	ENSG00000108878	Calcium voltage-gated channel auxiliary subunit gamma 1	17	67044590-67056797	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	25	skeletal muscle: 113.4	esophagus: 4.4	Cell line enhanced		HSkMC: 2.2;SH-SY5Y: 1.0
CALY	CALCYON, DRD1IP, NSG3	ENSG00000130643	Calcyon neuron specific vesicular protein	10	133324072-133336935	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042283	Enhanced				Pancreatic cancer:3.54e-4 (favourable)	Group enriched	Group enriched	13	adrenal gland: 23.5;cerebral cortex: 77.1	testis: 3.8	Not detected		
CAMLG	CAML, GET2	ENSG00000164615	Calcium modulating ligand	5	134738501-134752160	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052636, HPA056472	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:1.09e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 99.6	Expressed in all		
CARTPT	CART	ENSG00000164326	CART prepropeptide	5	71719163-71721048	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB025515, HPA046278	Enhanced				Stomach cancer:4.36e-4 (unfavourable)	Tissue enriched	Tissue enriched	8	adrenal gland: 132.5	cerebral cortex: 17.4	Not detected		
CASR	FHH, GPRC2A, HHC, HHC1, NSHPT	ENSG00000036828	Calcium sensing receptor	3	122183683-122291629	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039686, HPA050335	Enhanced					Tissue enriched	Tissue enriched	58	parathyroid gland: 1441.4	kidney: 24.6	Not detected		
CAT		ENSG00000121691	Catalase	11	34438925-34472062	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001515, HPA051282, HPA055838	Enhanced		Supported	Vesicles<br>Cytosol	Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable)	Expressed in all	Expressed in all			liver: 625.4	Cell line enhanced		HL-60: 310.1
CCKAR		ENSG00000163394	Cholecystokinin A receptor	4	26481400-26490462	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	10	gallbladder: 47.2;stomach: 15.2	tonsil: 3.1	Not detected		
CCKBR		ENSG00000110148	Cholecystokinin B receptor	11	6259736-6272127	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	13	cerebral cortex: 13.6;pancreas: 5.4;stomach: 16.4	prostate: 0.9	Cell line enriched	8	NTERA-2: 69.8
CCL2	GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF	ENSG00000108691	C-C motif chemokine ligand 2	17	34255218-34257203	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB013676, HPA019163	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:4.51e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 411.3	Group enriched	5	BJ hTERT+: 1539.3;BJ hTERT+ SV40 Large T+ RasG12V: 503.9;HMC-1: 2137.8
CCND1	BCL1, D11S287E, PRAD1, U21B31	ENSG00000110092	Cyclin D1	11	69641087-69654474	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000024, HPA027802	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 340.4	skin: 140.5	Cell line enhanced		WM-115: 1198.2
CCR5	CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22	ENSG00000160791	C-C motif chemokine receptor 5 (gene/pseudogene)	3	46370854-46376206	CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:7.42e-5 (favourable), Head and neck cancer:9.33e-5 (favourable)	Expressed in all	Mixed			appendix: 20.4	Group enriched	17	Karpas-707: 4.9;U-266/84: 2.1
CD19		ENSG00000177455	CD19 molecule	16	28931939-28939346	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB016110	Enhanced					Mixed	Group enriched	11	appendix: 37.4;lymph node: 84.0;spleen: 47.4;tonsil: 68.3	urinary bladder: 5.5	Group enriched	40	Daudi: 103.6;REH: 70.5;U-698: 22.6
CD2	SRBC	ENSG00000116824	CD2 molecule	1	116754385-116769228	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002430, HPA003883	Enhanced				Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 131.1	tonsil: 70.8	Group enriched	27	HDLM-2: 201.2;MOLT-4: 129.2
CD247	CD3H, CD3Q, CD3Z	ENSG00000198821	CD247 molecule	1	167430640-167518610	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004651, HPA008750	Enhanced				Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 65.1;spleen: 48.6	tonsil: 33.6	Group enriched	34	HDLM-2: 144.2;MOLT-4: 133.0
CD274	B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1	ENSG00000120217	CD274 molecule	9	5450503-5470566	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB030018, CAB076385	Enhanced		Approved	Cytosol	Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable)	Mixed	Mixed			appendix: 14.0	Cell line enhanced		HDLM-2: 82.8;HHSteC: 46.6;U-251 MG: 80.8
CD33	FLJ00391, p67, SIGLEC-3, SIGLEC3	ENSG00000105383	CD33 molecule	19	51225064-51243860	CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011442, HPA035832, HPA064807	Approved		Supported	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		spleen: 33.1	bone marrow: 20.9	Cell line enhanced		HEL: 77.8;HL-60: 92.6;HMC-1: 72.6;RPMI-8226: 43.3;THP-1: 45.3;U-937: 66.2
CD3D	T3D	ENSG00000167286	CD3d molecule	11	118338954-118342744	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013055	Enhanced				Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 199.3;tonsil: 119.1	appendix: 86.9	Cell line enriched	7	MOLT-4: 903.0
CD3E		ENSG00000198851	CD3e molecule	11	118304545-118316175	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB000010, HPA040957, HPA043955, CAB072863, CAB072864	Enhanced				Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 200.5;tonsil: 113.4	spleen: 95.0	Cell line enriched	92	MOLT-4: 531.3
CD3G		ENSG00000160654	CD3g molecule	11	118344344-118355161	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017520, HPA038494	Enhanced				Renal cancer:9.33e-5 (unfavourable), Cervical cancer:2.61e-4 (favourable), Head and neck cancer:3.00e-4 (favourable), Breast cancer:6.33e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 31.4;tonsil: 18.8	spleen: 16.1	Cell line enriched	69	MOLT-4: 160.9
CD4		ENSG00000010610	CD4 molecule	12	6786858-6820808	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000011, HPA004252, HPA004472, CAB068180	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 549.0	spleen: 220.5	Group enriched	5	HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
CD44	CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1	ENSG00000026508	CD44 molecule (Indian blood group)	11	35138870-35232402	Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000112, CAB000316, HPA005785	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane	Renal cancer:1.78e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 530.1	Mixed		
CD52	CDW52	ENSG00000169442	CD52 molecule	1	26317957-26320523	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable)	Expressed in all	Tissue enriched	35	epididymis: 43887.5	lymph node: 1251.0	Group enriched	8	Daudi: 505.6;REH: 946.6;U-266/84: 745.1;U-698: 783.6
CD80	B7-1, B7.1, CD28LG, CD28LG1	ENSG00000121594	CD80 molecule	3	119524293-119559602	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025368, HPA050092	Enhanced					Mixed	Tissue enhanced		appendix: 7.2;lymph node: 6.7;tonsil: 6.3	spleen: 4.7	Cell line enhanced		Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5
CD86	B7-2, B7.2, CD28LG2	ENSG00000114013	CD86 molecule	3	122055366-122121139	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004319	Uncertain				Renal cancer:9.83e-5 (unfavourable)	Expressed in all	Mixed			appendix: 47.8	Cell line enriched	10	HDLM-2: 275.8
CDK4	PSK-J3	ENSG00000135446	Cyclin dependent kinase 4	12	57747727-57756013	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006024, CAB013116, CAB069405	Enhanced		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cytosol	Liver cancer:2.09e-7 (unfavourable), Renal cancer:3.15e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 121.7	Group enriched	9	HBEC3-KT: 1874.1;LHCN-M2: 2370.6;RH-30: 8554.0
CDK6	PLSTIRE	ENSG00000105810	Cyclin dependent kinase 6	7	92604921-92836594	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002637, CAB004363	Enhanced		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 34.2	Cell line enhanced		MOLT-4: 366.7;REH: 201.1
CES1	CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1	ENSG00000198848	Carboxylesterase 1	16	55802851-55833337	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012023, HPA046717	Enhanced		Enhanced	Endoplasmic reticulum	Urothelial cancer:9.92e-4 (unfavourable)	Tissue enriched	Group enriched	7	gallbladder: 399.2;liver: 1099.9;lung: 229.9	adipose tissue: 79.7	Group enriched	5	Hep G2: 414.0;THP-1: 439.1;U-937: 102.6
CFTR	ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR	ENSG00000001626	Cystic fibrosis transmembrane conductance regulator	7	117465784-117715971	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001951, HPA021939	Enhanced				Liver cancer:9.44e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		gallbladder: 89.3	rectum: 49.0	Group enriched	19	CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9
CHD1		ENSG00000153922	Chromodomain helicase DNA binding protein 1	5	98853985-98928957	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022236	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.25e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 44.3	Expressed in all		
CHRM1		ENSG00000168539	Cholinergic receptor muscarinic 1	11	62908679-62921807	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014101, CAB022366	Enhanced		Approved	Nucleus<br>Cytosol		Tissue enriched	Group enriched	8	cerebral cortex: 39.9;prostate: 42.3;salivary gland: 11.0	adrenal gland: 3.8	Cell line enhanced		MCF7: 2.7;SK-BR-3: 1.2;T-47d: 1.0
CHRM2		ENSG00000181072	Cholinergic receptor muscarinic 2	7	136868669-137020255	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022338, HPA029795	Approved					Tissue enhanced	Tissue enhanced		gallbladder: 18.3;heart muscle: 25.8;smooth muscle: 13.7	urinary bladder: 5.9	Cell line enhanced		BJ: 14.1;BJ hTERT+: 15.2;fHDF/TERT166: 71.3;HHSteC: 10.8
CHRM3		ENSG00000133019	Cholinergic receptor muscarinic 3	1	239386565-239915452	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA024106, HPA048036	Approved		Supported	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 15.7	esophagus: 8.4	Cell line enhanced		RPMI-8226: 11.9;SH-SY5Y: 55.3;U-266/70: 16.6;U-266/84: 11.6
CHRM4		ENSG00000180720	Cholinergic receptor muscarinic 4	11	46385098-46386608	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022444, HPA072083	Uncertain		Uncertain	Nucleus<br>Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4	testis: 6.9	Cell line enhanced		RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0
CHRM5		ENSG00000184984	Cholinergic receptor muscarinic 5	15	33968720-34067457	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA013172	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.1;testis: 3.4	placenta: 2.3	Group enriched	7	BEWO: 4.5;HMC-1: 14.3
CHRNA10		ENSG00000129749	Cholinergic receptor nicotinic alpha 10 subunit	11	3665587-3671384	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	21	skeletal muscle: 16.6	appendix,lung: 0.7	Mixed		
CHRNA2		ENSG00000120903	Cholinergic receptor nicotinic alpha 2 subunit	8	27459761-27479883	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	24	prostate: 46.8	breast: 1.9	Not detected		
CHRNA3		ENSG00000080644	Cholinergic receptor nicotinic alpha 3 subunit	15	78593052-78621295	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029430	Approved					Mixed	Tissue enriched	8	adrenal gland: 48.0	appendix: 6.3	Group enriched	25	SCLC-21H: 72.3;SH-SY5Y: 343.0
CHRNA4	BFNC, EBN, EBN1	ENSG00000101204	Cholinergic receptor nicotinic alpha 4 subunit	20	63343223-63378401	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB034064	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 6.9;parathyroid gland: 17.4	liver: 3.9	Cell line enhanced		U-2 OS: 2.6
CHRNA7		ENSG00000175344	Cholinergic receptor nicotinic alpha 7 subunit	15	31923438-32173018	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029422, CAB033624	Enhanced					Mixed	Tissue enhanced		adrenal gland: 9.4;small intestine: 10.4	stomach: 6.2	Cell line enhanced		AN3-CA: 5.8;RT4: 9.8;SH-SY5Y: 7.1;SK-BR-3: 10.0;U-2 OS: 11.2
CHRNB2		ENSG00000160716	Cholinergic receptor nicotinic beta 2 subunit	1	154567781-154580026	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	15	cerebral cortex: 21.2	adrenal gland: 1.4	Group enriched	7	SCLC-21H: 30.2;SH-SY5Y: 27.0
CHRNB4		ENSG00000117971	Cholinergic receptor nicotinic beta 4 subunit	15	78624119-78727754	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 3.2;testis: 5.3	appendix: 0.8	Group enriched	23	SCLC-21H: 34.9;SH-SY5Y: 40.9
CKB	CKBB	ENSG00000166165	Creatine kinase B	14	103519659-103523111	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001254, CAB047313	Enhanced		Supported	Cytosol	Renal cancer:4.02e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 475.1	Cell line enhanced		CACO-2: 340.9;HEK93: 940.9;SCLC-21H: 678.1
CKM	CKMM	ENSG00000104879	Creatine kinase, M-type	19	45306414-45322977	Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047859	Enhanced					Group enriched	Tissue enriched	17	skeletal muscle: 23798.9	heart muscle: 1418.8	Cell line enriched	6	SCLC-21H: 75.4
CKMT1A	CKMT1	ENSG00000223572	Creatine kinase, mitochondrial 1A	15	43692886-43699222	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA043491	Uncertain					Mixed	Mixed			rectum: 73.8	Cell line enhanced		HaCaT: 113.0;SCLC-21H: 52.4;SK-BR-3: 74.4;T-47d: 83.6
CKMT1B	CKMT, CKMT1, UMTCK	ENSG00000237289	Creatine kinase, mitochondrial 1B	15	43593054-43604901	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA043491	Uncertain				Endometrial cancer:2.55e-5 (unfavourable)	Mixed	Tissue enhanced		colon: 78.0;rectum: 68.4	duodenum: 63.0	Cell line enhanced		HaCaT: 120.7;SCLC-21H: 60.9;SK-BR-3: 124.3;T-47d: 91.0
CKMT2	SMTCK	ENSG00000131730	Creatine kinase, mitochondrial 2	5	81233285-81266397	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051880	Enhanced					Mixed	Group enriched	22	heart muscle: 710.7;skeletal muscle: 505.3	adrenal gland: 27.9	Cell line enhanced		BEWO: 3.3;T-47d: 5.1
CLCN2	ClC-2, CLC2, EJM6	ENSG00000114859	Chloride voltage-gated channel 2	3	184346185-184361651	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009397, HPA014545, HPA024108	Approved		Approved	Cytosol	Liver cancer:4.67e-8 (unfavourable)	Expressed in all	Mixed			testis: 17.7	Mixed		
CNR1	CANN6, CB-R, CB1, CB1A, CB1K5, CNR	ENSG00000118432	Cannabinoid receptor 1	6	88139864-88166359	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		cerebral cortex: 32.1	adipose tissue: 12.2	Group enriched	7	ASC diff: 55.8;HSkMC: 39.1
CNR2	CB2	ENSG00000188822	Cannabinoid receptor 2	1	23870526-23913362	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009719	Uncertain					Tissue enriched	Group enriched	6	appendix: 3.1;lymph node: 8.7;spleen: 7.9;tonsil: 6.9	bone marrow: 1.0	Group enriched	5	Daudi: 3.8;HEL: 4.0;HMC-1: 17.3;U-698: 9.4
COMT		ENSG00000093010	Catechol-O-methyltransferase	22	19941607-19969975	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001169, CAB011233	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 172.6	Expressed in all		
CPS1		ENSG00000021826	Carbamoyl-phosphate synthase 1	2	210477682-210679107	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003781, HPA021400	Enhanced		Approved	Nucleoli	Liver cancer:6.93e-5 (favourable)	Tissue enriched	Group enriched	23	duodenum: 234.5;liver: 697.8;small intestine: 144.1	testis: 15.3	Cell line enhanced		HeLa: 249.1;SK-BR-3: 84.1
CPT1A	CPT1, CPT1-L, L-CPT1	ENSG00000110090	Carnitine palmitoyltransferase 1A	11	68754620-68844410	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008835	Enhanced		Supported	Mitochondria	Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 78.9	Mixed		
CPT2	CPT1, CPTASE	ENSG00000157184	Carnitine palmitoyltransferase 2	1	53196429-53214197	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028201, HPA028202, HPA028214	Enhanced		Supported	Nucleoplasm<br>Nucleoli<br>Mitochondria	Renal cancer:1.46e-12 (favourable), Colorectal cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			liver: 25.9	Expressed in all		
CRBN	MRT2, MRT2A	ENSG00000113851	Cereblon	3	3144628-3179727	Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045910	Approved		Approved	Nucleoli		Expressed in all	Expressed in all			testis: 87.7	Expressed in all		
CRHR1	CRF-R, CRF1, CRHR	ENSG00000120088	Corticotropin releasing hormone receptor 1	17	45784280-45835828	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB025251	Approved					Mixed	Tissue enhanced		cerebral cortex: 4.0	endometrium: 0.8	Cell line enhanced		RT4: 2.7;SH-SY5Y: 2.2
CSF1R	C-FMS, CD115, CSFR, FMS	ENSG00000182578	Colony stimulating factor 1 receptor	5	150053291-150113372	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB008970, HPA012323	Uncertain		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 147.7	Group enriched	6	BEWO: 118.6;SK-BR-3: 35.4
CSF2RA	CD116, CSF2R	ENSG00000198223	Colony stimulating factor 2 receptor alpha subunit	X	1268800-1310381	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016148	Uncertain				Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 93.3	appendix: 34.6	Group enriched	8	BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5
CSF2RB	CD131, IL3RB, IL5RB	ENSG00000100368	Colony stimulating factor 2 receptor beta common subunit	22	36913628-36940449	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA078677			Approved	Golgi apparatus	Head and neck cancer:7.47e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 89.7	tonsil: 57.2	Group enriched	7	HEL: 95.8;HMC-1: 281.8
CSF3R	CD114, GCSFR	ENSG00000119535	Colony stimulating factor 3 receptor	1	36466043-36483278	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017116, HPA048086	Enhanced				Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 211.2;bone marrow: 243.4;placenta: 147.9	spleen: 96.5	Cell line enhanced		BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3
CTLA4	CD, CD152, CELIAC3, GSE, IDDM12	ENSG00000163599	Cytotoxic T-lymphocyte associated protein 4	2	203867786-203873960	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:4.48e-5 (favourable)	Mixed	Tissue enhanced		appendix: 23.5;lymph node: 31.9	tonsil: 15.3	Group enriched	5	SK-MEL-30: 2.4;U-266/70: 3.5;U-266/84: 9.7
CXCR4	CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R	ENSG00000121966	C-X-C motif chemokine receptor 4	2	136114349-136118165	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.41e-7 (unfavourable), Ovarian cancer:2.05e-4 (favourable), Stomach cancer:5.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 771.6	tonsil: 495.9	Cell line enhanced		Daudi: 410.1;MOLT-4: 425.1;REH: 252.8;U-266/70: 489.0;U-698: 459.8
CYP11A1	CYP11A, P450SCC	ENSG00000140459	Cytochrome P450 family 11 subfamily A member 1	15	74337759-74367740	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016436	Enhanced					Mixed	Tissue enriched	11	adrenal gland: 748.5	testis: 68.5	Group enriched	25	BEWO: 102.7;HEL: 79.0;SiHa: 23.2
CYP11B1	CPN1, CYP11B, FHI, P450C11	ENSG00000160882	Cytochrome P450 family 11 subfamily B member 1	8	142872356-142879846	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049171, HPA056348, HPA057752	Supported					Not detected	Tissue enriched	916	adrenal gland: 1871.2	testis: 2.0	Not detected		
CYP17A1	CPT7, CYP17, P450C17, S17AH	ENSG00000148795	Cytochrome P450 family 17 subfamily A member 1	10	102830531-102837533	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA048533	Enhanced				Renal cancer:5.43e-7 (favourable)	Tissue enriched	Tissue enriched	25	adrenal gland: 3751.4	testis: 152.4	Cell line enhanced		HMC-1: 2.6;SCLC-21H: 1.3
CYP19A1	ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM	ENSG00000137869	Cytochrome P450 family 19 subfamily A member 1	15	51208057-51338610	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000355, HPA051194	Enhanced		Approved	Mitochondria		Mixed	Tissue enriched	15	placenta: 174.5	adrenal gland: 11.9	Group enriched	6	ASC TERT1: 65.0;HDLM-2: 16.2;HSkMC: 22.8
CYP51A1	CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1	ENSG00000001630	Cytochrome P450 family 51 subfamily A member 1	7	92112151-92142952	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041325, HPA043508	Enhanced		Enhanced	Endoplasmic reticulum	Cervical cancer:6.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 174.1	Expressed in all		
CYSLTR1	CysLT(1), CysLT1, CYSLT1R	ENSG00000173198	Cysteinyl leukotriene receptor 1	X	78271464-78327691	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010546	Approved					Mixed	Mixed			spleen: 14.8	Cell line enhanced		HL-60: 16.0;NB-4: 17.8;RPMI-8226: 29.5;THP-1: 17.5;U-937: 22.4
CYSLTR2	CysLT(2), CYSLT2R	ENSG00000152207	Cysteinyl leukotriene receptor 2	13	48653711-48711226	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046528	Uncertain					Group enriched	Tissue enhanced		placenta: 36.7;seminal vesicle: 25.0	spleen: 11.4	Cell line enriched	64	HDLM-2: 83.3
DBH	DBM	ENSG00000123454	Dopamine beta-hydroxylase	9	133636360-133659344	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002130, HPA005960, HPA070789	Enhanced		Enhanced	Endoplasmic reticulum<br>Vesicles		Mixed	Tissue enriched	28	adrenal gland: 356.8	liver: 12.6	Cell line enriched	370	SH-SY5Y: 1924.2
DCK		ENSG00000156136	Deoxycytidine kinase	4	70992538-71030914	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059609, HPA062773	Approved		Supported	Nucleus	Liver cancer:6.90e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 93.9	Expressed in all		
DDC	AADC	ENSG00000132437	Dopa decarboxylase	7	50458436-50565457	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017742	Enhanced		Approved	Actin filaments		Mixed	Tissue enhanced		duodenum: 155.2;kidney: 320.9;small intestine: 180.5	adrenal gland: 63.8	Group enriched	9	CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
DDR2	NTRKR3, TKT, TYRO10	ENSG00000162733	Discoidin domain receptor tyrosine kinase 2	1	162631373-162787400	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070112			Supported	Plasma membrane<br>Actin filaments	Renal cancer:1.73e-7 (unfavourable)	Expressed in all	Mixed			adrenal gland: 93.5	Cell line enhanced		ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DHFR		ENSG00000228716	Dihydrofolate reductase	5	80626228-80654983	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037129, HPA051465	Uncertain		Supported	Mitochondria		Expressed in all	Mixed			lymph node: 49.6	Expressed in all		
DHODH		ENSG00000102967	Dihydroorotate dehydrogenase (quinone)	16	72008588-72027664	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010123, HPA011942	Approved		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Mixed			liver: 21.4	Expressed in all		
DNMT1	CXXC9, DNMT, MCMT	ENSG00000130816	DNA methyltransferase 1	19	10133345-10231286	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002694, CAB005876	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 51.2	Expressed in all		
DPEP1		ENSG00000015413	Dipeptidase 1 (renal)	16	89613308-89638456	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA009426, HPA012783	Enhanced		Approved	Nucleus<br>Cell Junctions	Renal cancer:6.84e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 262.6;small intestine: 418.9	pancreas: 92.8	Cell line enhanced		Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
DPP4	ADCP2, CD26, DPPIV	ENSG00000197635	Dipeptidyl peptidase 4	2	161992241-162074542	CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB045970	Enhanced				Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 550.6	placenta: 169.1	Cell line enhanced		ASC diff: 115.0;ASC TERT1: 118.1;BJ hTERT+: 131.1;RPTEC TERT1: 175.8
DRD1		ENSG00000184845	Dopamine receptor D1	5	175440039-175444208	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013393		Supported				Mixed	Tissue enhanced		cerebral cortex: 8.0	prostate: 1.7	Group enriched	10	RT4: 20.9;U-2 OS: 5.4
DRD2		ENSG00000149295	Dopamine receptor D2	11	113409615-113475691	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015139, HPA015691	Supported	Supported				Mixed	Tissue enhanced		adrenal gland: 11.2	smooth muscle: 2.2	Cell line enriched	10	SCLC-21H: 104.3
DRD3		ENSG00000151577	Dopamine receptor D3	3	114128652-114199407	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	13	testis: 1.3	all non-specific tissues: 0.0	Not detected		
DRD4		ENSG00000069696	Dopamine receptor D4	11	637293-640706	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Not detected			skin: 0.3	Not detected		
DRD5	DRD1B, DRD1L2	ENSG00000169676	Dopamine receptor D5	4	9781680-9784009	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA048930	Supported					Not detected	Tissue enhanced		appendix: 1.7;cerebral cortex: 2.0;stomach: 3.8	testis: 0.8	Not detected		
EDNRA		ENSG00000151617	Endothelin receptor type A	4	147480917-147544954	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013774, CAB018957	Uncertain				Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 146.8	cervix, uterine: 83.0	Cell line enhanced		ASC TERT1: 11.8;LHCN-M2: 17.3;SH-SY5Y: 16.4
EDNRB	ETB, HSCR, HSCR2	ENSG00000136160	Endothelin receptor type B	13	77895481-77919768	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB017842, HPA027546	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.20e-5 (favourable)	Group enriched	Tissue enhanced		placenta: 180.2	cerebral cortex: 88.8	Cell line enhanced		AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
EGF		ENSG00000138798	Epidermal growth factor	4	109912884-110012266	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level							Mixed	Tissue enriched	7	kidney: 122.1	pancreas: 18.5	Cell line enhanced		EFO-21: 5.9;SK-BR-3: 8.5;U-251 MG: 3.0
EGFR	ERBB, ERBB1	ENSG00000146648	Epidermal growth factor receptor	7	55019021-55211628	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000035, HPA001200, HPA018530, CAB068186, CAB073534	Enhanced		Enhanced	Plasma membrane	Urothelial cancer:2.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 100.0	skin: 58.7	Cell line enriched	15	A-431: 4682.9
ELANE	ELA2, HLE, HNE, NE	ENSG00000197561	Elastase, neutrophil expressed	19	851014-856247	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB015409, HPA066836	Enhanced					Group enriched	Tissue enriched	320	bone marrow: 1199.6	skin: 3.7	Cell line enriched	56	THP-1: 1171.3
EPHA2	ECK	ENSG00000142627	EPH receptor A2	1	16124337-16156087	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010464			Supported	Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Tissue enhanced		esophagus: 86.8	gallbladder: 44.5	Cell line enhanced		PC-3: 211.2;WM-115: 253.0
EPOR		ENSG00000187266	Erythropoietin receptor	19	11377205-11384342	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA077613			Supported	Vesicles	Pancreatic cancer:3.17e-5 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 53.1	thyroid gland: 18.0	Mixed		
ERBB2	CD340, HER-2, HER2, NEU, NGL	ENSG00000141736	Erb-b2 receptor tyrosine kinase 2	17	39687914-39730426	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 124.5	Cell line enriched	22	SK-BR-3: 2343.7
ERBB4	ALS19, HER4	ENSG00000178568	Erb-b2 receptor tyrosine kinase 4	2	211375717-212538841	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000276, HPA012016, CAB025522	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 17.8	cerebral cortex: 7.6	Group enriched	5	AF22: 6.8;EFO-21: 4.8;HEK93: 3.5;RPTEC TERT1: 4.2;SCLC-21H: 3.7;T-47d: 4.8
ESR1	Era, ESR, NR3A1	ENSG00000091831	Estrogen receptor 1	6	151656691-152129619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000037, HPA000449, HPA000450, CAB055099, CAB072858	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.47e-7 (favourable)	Group enriched	Group enriched	8	breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5	seminal vesicle: 13.5	Group enriched	11	MCF7: 34.7;T-47d: 53.2
ESR2	Erb, NR3A2	ENSG00000140009	Estrogen receptor 2	14	64084232-64338112	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB065126	Enhanced					Not detected	Tissue enhanced		testis: 10.4	adrenal gland: 6.3	Cell line enhanced		U-266/70: 7.3;U-698: 11.3
ESRRG	NR3B3	ENSG00000196482	Estrogen related receptor gamma	1	216503246-217137755	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044678	Uncertain		Approved	Nucleus	Renal cancer:1.13e-11 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 77.5	kidney: 31.3	Group enriched	7	RPMI-8226: 16.0;SCLC-21H: 9.4;SH-SY5Y: 44.7
F10		ENSG00000126218	Coagulation factor X	13	113122814-113149529	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 67.5	cervix, uterine: 51.6	Cell line enhanced		BJ: 12.5;Hep G2: 40.8;SH-SY5Y: 30.0
F11	FXI	ENSG00000088926	Coagulation factor XI	4	186265945-186288806	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039808			Approved	Vesicles	Liver cancer:3.29e-5 (favourable)	Tissue enriched	Tissue enhanced		liver: 180.1	kidney: 44.7	Cell line enriched	8	Hep G2: 6.0
F12		ENSG00000131187	Coagulation factor XII	5	177402140-177409576	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003825	Approved				Liver cancer:4.63e-5 (favourable), Renal cancer:7.09e-4 (unfavourable)	Tissue enriched	Tissue enriched	78	liver: 141.6	bone marrow: 1.8	Cell line enhanced		HDLM-2: 6.4;MCF7: 6.7;PC-3: 5.8;SH-SY5Y: 4.5
F2		ENSG00000180210	Coagulation factor II, thrombin	11	46719180-46739506	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016780, CAB018650, HPA051476, HPA054698	Enhanced				Renal cancer:6.75e-12 (unfavourable)	Tissue enriched	Tissue enriched	1472	liver: 627.3	testis: 0.4	Cell line enriched	18	Hep G2: 186.7
F2R	CF2R, PAR-1, PAR1, TR	ENSG00000181104	Coagulation factor II thrombin receptor	5	76716043-76735781	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB008973, CAB012962	Approved				Renal cancer:2.21e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 94.1	Cell line enhanced		HUVEC TERT2: 297.4;WM-115: 331.7
F3	CD142, TF	ENSG00000117525	Coagulation factor III, tissue factor	1	94529225-94541800	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009438, HPA049292, HPA069132	Approved		Enhanced	Vesicles	Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 191.1	Cell line enhanced		A-431: 929.2;HaCaT: 433.2;HBEC3-KT: 914.1;U-2197: 442.4
F5		ENSG00000198734	Coagulation factor V	1	169514166-169586588	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002036	Uncertain		Approved	Golgi apparatus	Stomach cancer:3.39e-4 (unfavourable)	Tissue enriched	Group enriched	11	gallbladder: 28.4;liver: 93.7;placenta: 68.2	fallopian tube: 5.9	Cell line enriched	7	Hep G2: 22.8
F7		ENSG00000057593	Coagulation factor VII	13	113105788-113120681	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004826			Approved	Mitochondria		Tissue enriched	Tissue enriched	44	liver: 65.0	testis: 1.4	Group enriched	7	CACO-2: 11.8;Hep G2: 6.1
F8	DXS1253E, F8C, FVIII, HEMA	ENSG00000185010	Coagulation factor VIII	X	154835788-155026940	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018777	Enhanced					Expressed in all	Expressed in all			lung: 23.4	Mixed		
F9	FIX	ENSG00000101981	Coagulation factor IX	X	139530758-139563458	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:6.69e-4 (favourable)	Tissue enriched	Tissue enriched	2258	liver: 365.0	kidney: 0.1	Not detected		
FADS1	D5D, FADS6, FADSD5, LLCDL1, TU12	ENSG00000149485	Fatty acid desaturase 1	11	61799625-61829318	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042705	Approved				Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 89.1	Expressed in all		
FADS2	D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13	ENSG00000134824	Fatty acid desaturase 2	11	61792980-61867354	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006741	Approved				Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 414.3	Expressed in all		
FASN	FAS, SDR27X1	ENSG00000169710	Fatty acid synthase	17	82078333-82098332	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005192, HPA006461, CAB015417, HPA056108	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 290.7	Expressed in all		
FCER1A	FCE1A	ENSG00000179639	Fc fragment of IgE receptor Ia	1	159289714-159308224	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB022102, HPA036051, CAB055526	Approved				Renal cancer:1.20e-4 (favourable)	Expressed in all	Mixed			skin: 39.9	Cell line enriched	100	HEL: 401.2
FCER1G		ENSG00000158869	Fc fragment of IgE receptor Ig	1	161215234-161220699	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB022108, HPA026872	Supported				Renal cancer:1.83e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 462.9	Group enriched	5	HEL: 69.1;HMC-1: 265.2;THP-1: 185.7;U-266/84: 61.5;U-937: 67.6
FCGR1A	CD64, CD64A	ENSG00000150337	Fc fragment of IgG receptor Ia	1	149782671-149792518	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.83e-8 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 91.1	appendix: 48.9	Cell line enriched	5	THP-1: 113.9
FCGR1B	CD64b	ENSG00000198019	Fc fragment of IgG receptor Ib	1	121087345-121096310	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		appendix: 27.5;epididymis: 61.7	placenta: 17.0	Cell line enhanced		HMC-1: 6.6;NB-4: 12.8;THP-1: 51.9
FCGR2A	CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2	ENSG00000143226	Fc fragment of IgG receptor IIa	1	161505430-161524013	CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010718, HPA014730	Enhanced				Renal cancer:6.49e-7 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 160.6	appendix: 148.6	Cell line enhanced		HEL: 26.6;HMC-1: 50.4;K-562: 16.0;THP-1: 42.6;U-937: 21.3
FCGR2B	CD32, CD32B, FCG2, FCGR2	ENSG00000072694	Fc fragment of IgG receptor IIb	1	161663147-161678654	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB007796, HPA014730	Enhanced				Renal cancer:8.82e-4 (unfavourable)	Mixed	Tissue enriched	16	placenta: 576.7	adipose tissue: 36.6	Cell line enhanced		Daudi: 18.5;HMC-1: 27.5;RPMI-8226: 8.1
FCGR3A	CD16, CD16a, FCG3, FCGR3	ENSG00000203747	Fc fragment of IgG receptor IIIa	1	161541759-161550737	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032435, HPA055431	Supported				Renal cancer:3.22e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 419.4	Not detected		
FCGR3B	CD16, CD16b, FCG3, FCGR3	ENSG00000162747	Fc fragment of IgG receptor IIIb	1	161623196-161631963	CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 118.1;spleen: 115.2	urinary bladder: 36.3	Not detected		
FDPS		ENSG00000160752	Farnesyl diphosphate synthase	1	155308748-155320666	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028200	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 186.4	Expressed in all		
FFAR1	FFA1R, GPR40	ENSG00000126266	Free fatty acid receptor 1	19	35351552-35353862	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		bone marrow: 1.9	ovary: 1.2	Cell line enhanced		U-698: 1.1
FGA		ENSG00000171560	Fibrinogen alpha chain	4	154583126-154590766	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016776, HPA051370, HPA064755	Supported				Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable)	Tissue enriched	Tissue enriched	237	liver: 9265.4	stomach: 39.0	Cell line enriched	11	Hep G2: 285.6
FGF1	AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1	ENSG00000113578	Fibroblast growth factor 1	5	142592178-142698070	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003265, CAB017519	Enhanced				Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 129.9;kidney: 59.4	heart muscle: 32.8	Cell line enhanced		BJ: 37.6;BJ hTERT+ SV40 Large T+: 33.4;BJ hTERT+ SV40 Large T+ RasG12V: 43.9;HBF TERT88: 62.3;hTEC/SVTERT24-B: 45.5;U-2 OS: 33.6
FGF2	FGFB	ENSG00000138685	Fibroblast growth factor 2	4	122826708-122898236	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB000125	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:9.85e-4 (unfavourable)	Mixed	Mixed			adipose tissue: 26.1	Cell line enhanced		BJ: 206.0;fHDF/TERT166: 215.4
FGFR1	BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM	ENSG00000077782	Fibroblast growth factor receptor 1	8	38411138-38468834	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB033614, HPA056402, HPA076274	Approved		Supported	Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 109.5	Cell line enhanced		AN3-CA: 602.2
FGFR2	BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25	ENSG00000066468	Fibroblast growth factor receptor 2	10	121478334-121598458	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010886, HPA035305, HPA056562	Uncertain		Approved	Vesicles	Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)	Expressed in all	Mixed			skin: 129.4	Cell line enhanced		AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFR3	ACH, CD333, CEK2, JTK4	ENSG00000068078	Fibroblast growth factor receptor 3	4	1793307-1808872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB004231, HPA067204	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skin: 333.1	cerebral cortex: 49.4	Cell line enhanced		CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
FGFR4	CD334, JTK2	ENSG00000160867	Fibroblast growth factor receptor 4	5	177086886-177098144	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005196, HPA027273, HPA027369, HPA028251	Approved					Mixed	Tissue enhanced		lung: 38.9	duodenum: 21.4	Cell line enhanced		CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
FKBP1A	FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE	ENSG00000088832	FK506 binding protein 1A	20	1368978-1393172	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004639, HPA051798	Uncertain				Liver cancer:3.44e-7 (unfavourable), Renal cancer:6.69e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 369.7	Expressed in all		
FLT1	FLT, VEGFR1	ENSG00000102755	Fms related tyrosine kinase 1	13	28300344-28495145	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA011740, HPA014290, CAB068189, CAB068190	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:2.19e-4 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 622.5	thyroid gland: 81.9	Cell line enhanced		BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
FLT3	CD135, FLK2, STK1	ENSG00000122025	Fms related tyrosine kinase 3	13	28003274-28100592	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA047539			Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		lymph node: 7.0;spleen: 7.7	appendix: 3.9	Group enriched	14	REH: 38.7;THP-1: 17.4
FLT4	PCL, VEGFR3	ENSG00000037280	Fms related tyrosine kinase 4	5	180601506-180649624	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000099, HPA046519, HPA067906	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			spleen: 18.3	Cell line enhanced		BEWO: 11.8;HEK93: 14.1;T-47d: 13.7;TIME: 12.7
FN1	CIG, FINC, GFND2, LETS, MSF	ENSG00000115414	Fibronectin 1	2	215360440-215436172	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000126, HPA027066	Enhanced				Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 4284.3	lung: 1167.5	Cell line enhanced		ASC TERT1: 24376.9;HSkMC: 11926.5;hTERT-HME1: 7509.7
FOLH1	FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA	ENSG00000086205	Folate hydrolase 1	11	49146635-49208670	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001451, HPA010593	Enhanced				Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable)	Tissue enriched	Group enriched	6	duodenum: 298.8;prostate: 136.6;small intestine: 90.8	cerebral cortex: 31.0	Mixed		
FRK	GTK, PTK5, RAK	ENSG00000111816	Fyn related Src family tyrosine kinase	6	115931149-116060758	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025217, HPA030479	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:9.66e-7 (favourable)	Mixed	Mixed			kidney: 10.0	Mixed		
FSHR	FSHRO, LGR1, ODG1	ENSG00000170820	Follicle stimulating hormone receptor	2	48962157-49154537	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Group enriched	9	ovary: 2.5;testis: 4.3	gallbladder: 0.3	Not detected		
FTH1	FHC, FTH, FTHL6, PIG15, PLIF	ENSG00000167996	Ferritin heavy chain 1	11	61959718-61967660	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008623	Approved		Approved	Microtubules	Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 4962.3	Expressed in all		
FTL	MGC71996, NBIA3	ENSG00000087086	Ferritin light chain	19	48965301-48966878	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB020769, HPA041602	Enhanced		Approved	Cytosol	Renal cancer:4.40e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 8050.1	Expressed in all		
FXYD2	ATP1G1, HOMG2, MGC12372	ENSG00000137731	FXYD domain containing ion transport regulator 2	11	117800844-117828698	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064218, HPA068838	Supported		Approved	Mitochondria	Renal cancer:3.23e-9 (favourable)	Tissue enriched	Group enriched	6	gallbladder: 571.3;kidney: 1433.1;salivary gland: 380.4	pancreas: 134.6	Group enriched	24	MOLT-4: 1801.2;RPTEC TERT1: 3683.4
GAA		ENSG00000171298	Glucosidase alpha, acid	17	80101556-80119879	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026970, HPA029126	Enhanced				Colorectal cancer:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 69.7	Mixed		
GABBR1	GPRC3A, hGB1a	ENSG00000204681	Gamma-aminobutyric acid type B receptor subunit 1	6	29555629-29633976	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050483, HPA058459	Uncertain		Approved	Centrosome	Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 20.8	spleen: 13.1	Cell line enhanced		U-2 OS: 6.7
GABBR2	GABABR2, GPR51, GPRC3B, HG20	ENSG00000136928	Gamma-aminobutyric acid type B receptor subunit 2	9	98288082-98709197	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013820, HPA031684, CAB079065	Enhanced	Approved				Group enriched	Tissue enriched	18	cerebral cortex: 77.9	adrenal gland: 4.3	Cell line enhanced		BJ: 11.3;HUVEC TERT2: 22.8;U-138 MG: 10.3
GABRA1	EJM5	ENSG00000022355	Gamma-aminobutyric acid type A receptor alpha1 subunit	5	161847063-161899981	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022502, HPA055746	Enhanced					Tissue enriched	Tissue enriched	46	cerebral cortex: 85.0	adrenal gland: 1.8	Not detected		
GABRA2		ENSG00000151834	Gamma-aminobutyric acid type A receptor alpha2 subunit	4	46248427-46475230	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB079061		Supported				Tissue enhanced	Tissue enriched	7	cerebral cortex: 74.3	epididymis: 11.3	Cell line enhanced		U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5
GABRA3		ENSG00000011677	Gamma-aminobutyric acid type A receptor alpha3 subunit	X	152166234-152451358	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA000839	Approved	Supported				Tissue enriched	Tissue enriched	7	cerebral cortex: 28.8	placenta: 4.1	Cell line enhanced		HMC-1: 7.4;Karpas-707: 10.3;PC-3: 7.8;U-2 OS: 7.3;U-266/84: 9.5;U-87 MG: 8.1
GABRA4		ENSG00000109158	Gamma-aminobutyric acid type A receptor alpha4 subunit	4	46918900-46994407	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	9	cerebral cortex: 15.1	heart muscle: 1.6	Cell line enriched	127	REH: 12.7
GABRA5		ENSG00000186297	Gamma-aminobutyric acid type A receptor alpha5 subunit	15	26866363-26949207	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077031, CAB079022		Supported	Supported	Plasma membrane		Mixed	Tissue enriched	43	cerebral cortex: 81.6	esophagus: 1.8	Group enriched	10	A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
GABRA6		ENSG00000145863	Gamma-aminobutyric acid type A receptor alpha6 subunit	5	161547063-161702593	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	CAB022462	Approved					Not detected	Tissue enhanced		testis: 1.1	cerebral cortex: 0.3	Not detected		
GABRB1		ENSG00000163288	Gamma-aminobutyric acid type A receptor beta1 subunit	4	46993723-47426444	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051297	Uncertain					Tissue enhanced	Tissue enriched	12	cerebral cortex: 19.7	heart muscle: 1.5	Cell line enhanced		REH: 1.4;U-87 MG: 2.4
GABRB2		ENSG00000145864	Gamma-aminobutyric acid type A receptor beta2 subunit	5	161288429-161549044	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001964, HPA067632	Enhanced					Tissue enriched	Tissue enriched	12	cerebral cortex: 62.8	epididymis: 5.2	Cell line enriched	17	SCLC-21H: 27.6
GABRB3		ENSG00000166206	Gamma-aminobutyric acid type A receptor beta3 subunit	15	26543546-26939539	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 78.3	gallbladder: 21.5	Cell line enhanced		A549: 61.5;HAP1: 28.7;NTERA-2: 48.0;SCLC-21H: 51.8
GABRD		ENSG00000187730	Gamma-aminobutyric acid type A receptor delta subunit	1	2019298-2030758	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044371	Enhanced		Uncertain	Golgi apparatus<br>Vesicles	Renal cancer:4.12e-8 (unfavourable)	Expressed in all	Tissue enriched	12	cerebral cortex: 34.0	testis: 2.7	Cell line enhanced		EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
GABRE		ENSG00000102287	Gamma-aminobutyric acid type A receptor epsilon subunit	X	151953124-151974680	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA045918	Uncertain				Renal cancer:4.05e-11 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 10.1	heart muscle: 6.4	Cell line enhanced		EFO-21: 10.9;HeLa: 3.5;SiHa: 5.9
GABRG1		ENSG00000163285	Gamma-aminobutyric acid type A receptor gamma1 subunit	4	46035769-46124081	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA035622	Approved					Tissue enriched	Tissue enriched	17	cerebral cortex: 26.0	ovary: 1.5	Cell line enhanced		U-266/70: 1.1
GABRG2		ENSG00000113327	Gamma-aminobutyric acid type A receptor gamma2 subunit	5	162000057-162162977	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB079060		Supported				Tissue enhanced	Tissue enriched	12	cerebral cortex: 66.5	adrenal gland: 5.3	Cell line enhanced		CACO-2: 11.6;U-266/70: 17.2;U-266/84: 13.6
GABRG3		ENSG00000182256	Gamma-aminobutyric acid type A receptor gamma3 subunit	15	26971282-27541991	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054010	Supported					Tissue enhanced	Tissue enhanced		prostate: 10.6;testis: 16.5	cerebral cortex: 4.2	Cell line enhanced		K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
GABRP		ENSG00000094755	Gamma-aminobutyric acid type A receptor pi subunit	5	170763350-170814047	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB014883	Uncertain				Cervical cancer:3.37e-4 (favourable)	Mixed	Expressed in all			breast: 177.0	Cell line enhanced		A-431: 184.7;EFO-21: 182.4;PC-3: 293.8
GABRQ	THETA	ENSG00000268089	Gamma-aminobutyric acid type A receptor theta subunit	X	152638183-152657534	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6;cervix, uterine: 12.9	adrenal gland: 3.0	Group enriched	7	HeLa: 8.2;SiHa: 12.7;U-87 MG: 37.4
GABRR1		ENSG00000146276	Gamma-aminobutyric acid type A receptor rho1 subunit	6	89177501-89231278	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.8	placenta: 0.3	Cell line enhanced		NTERA-2: 1.2
GABRR2		ENSG00000111886	Gamma-aminobutyric acid type A receptor rho2 subunit	6	89257208-89315299	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland,appendix,cerebral cortex,endometrium,gallbladder,lymph node,skin,spleen,testis,thyroid gland: 0.1	Not detected		
GABRR3		ENSG00000183185	Gamma-aminobutyric acid type A receptor rho3 subunit (gene/pseudogene)	3	97986673-98035304	FDA approved drug targets, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
GAMT	PIG2, TP53I2	ENSG00000130005	Guanidinoacetate N-methyltransferase	19	1397026-1401570	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051806	Approved				Stomach cancer:6.57e-4 (unfavourable)	Tissue enriched	Group enriched	5	epididymis: 173.0;liver: 158.9;skeletal muscle: 425.6	pancreas: 48.1	Mixed		
GANAB	G2AN, GIIA, GluII, KIAA0088	ENSG00000089597	Glucosidase II alpha subunit	11	62624826-62646726	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026874, HPA061426	Enhanced		Approved	Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol	Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 295.2	Expressed in all		
GANC		ENSG00000214013	Glucosidase alpha, neutral C	15	42273233-42356935	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016949	Approved		Approved	Nucleoplasm<br>Actin filaments	Lung cancer:9.76e-4 (favourable)	Expressed in all	Expressed in all			lung: 29.8	Expressed in all		
GART	PGFT, PRGS	ENSG00000159131	Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	21	33503931-33543491	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002119, HPA005779	Approved		Uncertain	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:3.95e-6 (unfavourable), Head and neck cancer:5.05e-5 (unfavourable), Liver cancer:9.82e-5 (unfavourable), Pancreatic cancer:2.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 55.1	Expressed in all		
GCGR	GGR	ENSG00000215644	Glucagon receptor	17	81804132-81814013	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071228			Approved	Golgi apparatus		Tissue enhanced	Group enriched	7	adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0	skin: 1.6	Cell line enhanced		HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
GGCX	VKCFD1	ENSG00000115486	Gamma-glutamyl carboxylase	2	85544723-85561547	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA018284	Approved				Endometrial cancer:1.82e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 61.3	Expressed in all		
GGPS1	GGPPS1	ENSG00000152904	Geranylgeranyl diphosphate synthase 1	1	235327350-235344532	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029472	Enhanced				Liver cancer:6.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 90.1	Expressed in all		
GHR	GHBP	ENSG00000112964	Growth hormone receptor	5	42423777-42721878	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA045339, HPA057705	Enhanced		Supported	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Liver cancer:2.73e-6 (favourable)	Mixed	Group enriched	6	adipose tissue: 91.4;liver: 110.5	prostate: 18.0	Group enriched	7	HSkMC: 15.4;T-47d: 52.5
GHRHR		ENSG00000106128	Growth hormone releasing hormone receptor	7	30938669-30993254	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Not detected			adrenal gland: 0.5	Not detected		
GLP1R		ENSG00000112164	Glucagon like peptide 1 receptor	6	39048798-39087743	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 1.9;heart muscle: 1.8	pancreas: 1.5	Cell line enhanced		NTERA-2: 1.3;SCLC-21H: 3.7
GLP2R		ENSG00000065325	Glucagon like peptide 2 receptor	17	9822206-9892102	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022690, HPA049244	Supported		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		gallbladder: 19.3	duodenum: 10.1	Cell line enhanced		A549: 15.1;HeLa: 54.7;SiHa: 8.7
GLRA1	STHE	ENSG00000145888	Glycine receptor alpha 1	5	151822513-151924842	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016502, CAB079042	Uncertain	Supported				Not detected	Not detected			adrenal gland: 0.4	Not detected		
GLRA2	GLR	ENSG00000101958	Glycine receptor alpha 2	X	14529298-14731812	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB070422	Approved					Mixed	Group enriched	10	cerebral cortex: 6.1;colon: 1.4;rectum: 4.3	testis: 0.3	Cell line enriched	41	AN3-CA: 16.1
GLRA3		ENSG00000145451	Glycine receptor alpha 3	4	174636914-174829314	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Group enriched	6	breast: 2.6;cerebral cortex: 9.1	adrenal gland: 1.0	Cell line enhanced		Karpas-707: 1.4
GLRB		ENSG00000109738	Glycine receptor beta	4	157076057-157172090	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052363	Approved				Renal cancer:4.89e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 62.0;parathyroid gland: 63.1	cervix, uterine: 14.1	Mixed		
GNRHR	GRHR, LHRHR	ENSG00000109163	Gonadotropin releasing hormone receptor	4	67739328-67754360	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013424	Supported					Not detected	Tissue enhanced		adrenal gland: 1.0	cerebral cortex: 0.6	Not detected		
GRIA1	GluA1, GLUR1, GLURA	ENSG00000155511	Glutamate ionotropic receptor AMPA type subunit 1	5	153489615-153813869	FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB001965, HPA035202	Supported					Tissue enriched	Tissue enriched	6	cerebral cortex: 67.1	lung: 10.6	Cell line enhanced		AF22: 11.5;BJ: 4.7;LHCN-M2: 6.9;U-266/70: 4.4
GRIK1	GluK1, GLUR5	ENSG00000171189	Glutamate ionotropic receptor kainate type subunit 1	21	29536933-29940033	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA014623	Uncertain				Glioma:9.12e-4 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 16.3;cerebral cortex: 9.0	prostate: 4.0	Not detected		
GRIN1	GluN1, NMDAR1	ENSG00000176884	Glutamate ionotropic receptor NMDA type subunit 1	9	137138390-137168762	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB006831	Approved					Mixed	Tissue enriched	208	cerebral cortex: 151.8	prostate: 0.7	Cell line enhanced		RPMI-8226: 1.8;SCLC-21H: 6.7;SH-SY5Y: 4.2
GRIN2A	GluN2A, NMDAR2A	ENSG00000183454	Glutamate ionotropic receptor NMDA type subunit 2A	16	9753404-10182754	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB022725	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 25.8	testis: 6.1	Cell line enhanced		fHDF/TERT166: 3.3;U-138 MG: 4.4
GRIN2B	GluN2B, NMDAR2B	ENSG00000273079	Glutamate ionotropic receptor NMDA type subunit 2B	12	13437942-13981957	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA069762	Approved					Not detected	Tissue enriched	23	cerebral cortex: 13.1	adipose tissue,testis: 0.5	Cell line enhanced		AF22: 1.2;CACO-2: 1.2;NTERA-2: 1.8;RPTEC TERT1: 1.3
GRIN2C	GluN2C, NMDAR2C	ENSG00000161509	Glutamate ionotropic receptor NMDA type subunit 2C	17	74842023-74861504	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 9.5;thyroid gland: 14.1	heart muscle: 6.1	Cell line enhanced		BEWO: 6.1;SCLC-21H: 3.3
GRIN2D	EB11, GluN2D, NMDAR2D, NR2D	ENSG00000105464	Glutamate ionotropic receptor NMDA type subunit 2D	19	48394875-48444931	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 2.3	placenta: 1.3	Cell line enhanced		A549: 16.7;HMC-1: 27.0
GRIN3A	GluN3A	ENSG00000198785	Glutamate ionotropic receptor NMDA type subunit 3A	9	101569353-101738580	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	5	cerebral cortex: 12.3;cervix, uterine: 2.5	seminal vesicle: 1.3	Cell line enriched	6	SCLC-21H: 2.1
GRIN3B	GluN3B	ENSG00000116032	Glutamate ionotropic receptor NMDA type subunit 3B	19	1000419-1009732	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		fallopian tube: 2.1;spleen: 1.2	lung: 0.7	Cell line enhanced		U-266/70: 2.6
GRM5	GPRC1E, mGlu5, MGLUR5, PPP1R86	ENSG00000168959	Glutamate metabotropic receptor 5	11	88504576-89065945	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	8	cerebral cortex: 27.2	testis: 3.2	Not detected		
GSR		ENSG00000104687	Glutathione-disulfide reductase	8	30678061-30727926	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001538, CAB008632	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 79.3	Expressed in all		
GSS		ENSG00000100983	Glutathione synthetase	20	34928430-34955817	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054508, HPA059315	Enhanced		Supported	Nucleus	Renal cancer:7.31e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 105.8	Expressed in all		
GUCY1A2	GC-SA2, GUC1A2	ENSG00000152402	Guanylate cyclase 1 soluble subunit alpha 2	11	106674012-107018524	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009534	Uncertain				Renal cancer:3.02e-5 (unfavourable)	Mixed	Tissue enhanced		placenta: 25.6	endometrium: 21.1	Cell line enhanced		BJ hTERT+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 6.9
GUCY2C	GUC2C, STAR	ENSG00000070019	Guanylate cyclase 2C	12	14612632-14696585	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037655, HPA073759	Uncertain		Uncertain	Vesicles	Liver cancer:1.37e-5 (unfavourable)	Group enriched	Group enriched	13	colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2	appendix: 4.4	Cell line enhanced		AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
HBA1	HBA-T3	ENSG00000206172	Hemoglobin subunit alpha 1	16	176680-177522	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB032534, HPA043780	Enhanced					Tissue enhanced	Group enriched	34	bone marrow: 17119.3;placenta: 3433.6	spleen: 303.5	Group enriched	51	HEL: 3255.0;K-562: 2173.8
HBA2	HBA-T2	ENSG00000188536	Hemoglobin subunit alpha 2	16	172847-173710	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB038417, HPA043780	Enhanced					Expressed in all	Group enriched	27	bone marrow: 18369.0;placenta: 4302.7	spleen: 427.2	Group enriched	18	HEL: 802.0;K-562: 265.1
HBB	beta-globin, CD113t-C, HBD	ENSG00000244734	Hemoglobin subunit beta	11	5225464-5229395	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009526, HPA043234	Enhanced		Approved	Vesicles		Expressed in all	Tissue enriched	9	bone marrow: 78046.6	placenta: 9082.6	Cell line enhanced		HEL: 5.3;SCLC-21H: 5.9;SH-SY5Y: 6.7;U-266/70: 17.4
HCAR2	GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG	ENSG00000182782	Hydroxycarboxylic acid receptor 2	12	122701293-122703343	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028660	Approved		Approved	Cell Junctions		Group enriched	Tissue enhanced		spleen: 36.0	esophagus: 25.5	Cell line enriched	7	HaCaT: 105.3
HCAR3	GPR109B, HCA3, HM74	ENSG00000255398	Hydroxycarboxylic acid receptor 3	12	122714756-122716892	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028660	Approved		Approved	Cell Junctions		Mixed	Tissue enhanced		bone marrow: 16.6;spleen: 21.7	appendix: 12.4	Group enriched	6	HaCaT: 8.1;RT4: 28.3
HCRTR1	OX1R	ENSG00000121764	Hypocretin receptor 1	1	31617686-31632518	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014018	Approved					Not detected	Tissue enhanced		adrenal gland: 1.2	cerebral cortex: 0.9	Not detected		
HCRTR2	OX2R	ENSG00000137252	Hypocretin receptor 2	6	55106460-55282620	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA054516	Supported					Not detected	Not detected			kidney: 0.6	Cell line enriched	7	AF22: 1.0
HDAC1	GON-10, HD1, RPD3L1	ENSG00000116478	Histone deacetylase 1	1	32292086-32333635	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005017, HPA029693, CAB068191	Enhanced		Enhanced	Nucleoplasm	Liver cancer:5.76e-7 (unfavourable), Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 139.0	Expressed in all		
HDAC10	DKFZP761B039	ENSG00000100429	Histone deacetylase 10	22	50245183-50251405	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB045977, HPA056514	Supported		Approved	Nucleoli fibrillar center	Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable)	Expressed in all	Mixed			spleen: 9.8	Mixed		
HDAC11		ENSG00000163517	Histone deacetylase 11	3	13479724-13506424	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.88e-10 (favourable), Liver cancer:1.20e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 66.7	Cell line enhanced		T-47d: 39.9
HDAC2	RPD3, YAF1	ENSG00000196591	Histone deacetylase 2	6	113933028-114011308	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005054, HPA011727	Supported		Enhanced	Nucleus	Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 141.1	Expressed in all		
HDAC3	HD3, RPD3, RPD3-2	ENSG00000171720	Histone deacetylase 3	5	141620876-141636870	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005583, HPA052052	Supported		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.65e-6 (unfavourable), Colorectal cancer:3.39e-4 (favourable), Pancreatic cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.1	Expressed in all		
HDAC4	BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288	ENSG00000068024	Histone deacetylase 4	2	239048168-239401654	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004431, HPA048723	Approved		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.13e-4 (favourable), Ovarian cancer:6.33e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 19.3	Cell line enhanced		MOLT-4: 40.5
HDAC5	FLJ90614, KIAA0600, NY-CO-9	ENSG00000108840	Histone deacetylase 5	17	44076746-44123702	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB019400, HPA030991	Approved		Supported	Nuclear speckles<br>Golgi apparatus<br>Cytosol	Liver cancer:3.12e-5 (unfavourable), Renal cancer:3.30e-5 (favourable), Cervical cancer:6.14e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.0	Mixed		
HDAC6	FLJ16239, HD6, JM21, KIAA0901, PPP1R90	ENSG00000094631	Histone deacetylase 6	X	48801377-48824982	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003714, CAB004236, HPA026321	Approved		Supported	Nucleoplasm	Urothelial cancer:3.34e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.4	Expressed in all		
HDAC7	DKFZP586J0917, HDAC7A	ENSG00000061273	Histone deacetylase 7	12	47782722-47833132	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004775			Supported	Cytosol	Urothelial cancer:4.65e-4 (favourable), Melanoma:5.16e-4 (unfavourable), Renal cancer:8.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 43.9	Expressed in all		
HDAC8	HDACL1, MRXS6, RPD3, WTS	ENSG00000147099	Histone deacetylase 8	X	72329516-72573103	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048560	Supported		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			epididymis: 27.1	Expressed in all		
HDAC9	HD7, HDAC, HDAC7B, KIAA0744, MITR	ENSG00000048052	Histone deacetylase 9	7	18086949-19002416	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028926	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			spleen: 24.6	Cell line enhanced		HAP1: 176.1;SH-SY5Y: 71.2
HMGCR		ENSG00000113161	3-hydroxy-3-methylglutaryl-CoA reductase	5	75336329-75362104	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008338, CAB016797	Approved				Renal cancer:9.42e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 87.5	Expressed in all		
HMMR	CD168, RHAMM	ENSG00000072571	Hyaluronan mediated motility receptor	5	163460203-163491945	CD markers, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002433, HPA040025, HPA043926, HPA061524	Enhanced		Enhanced	Microtubules<br>Centrosome<br>Cytosol	Liver cancer:1.93e-7 (unfavourable), Pancreatic cancer:3.71e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Head and neck cancer:5.52e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 49.7	lymph node: 21.7	Expressed in all		
HPD	4-HPPD, 4HPPD, GLOD3, PPD	ENSG00000158104	4-hydroxyphenylpyruvate dioxygenase	12	121839527-121863596	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038321, HPA038322	Enhanced		Uncertain	Nuclear speckles		Tissue enriched	Group enriched	86	kidney: 529.9;liver: 1293.2	seminal vesicle: 10.5	Cell line enriched	24	Hep G2: 349.1
HPRT1	HGPRT, HPRT	ENSG00000165704	Hypoxanthine phosphoribosyltransferase 1	X	134460153-134520513	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006360, CAB012200	Enhanced		Supported	Cytosol	Head and neck cancer:1.35e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 139.1	Mixed		
HRH1		ENSG00000196639	Histamine receptor H1	3	11137093-11263557	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029740	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.27e-5 (unfavourable)	Mixed	Mixed			cerebral cortex: 12.4	Mixed		
HRH2		ENSG00000113749	Histamine receptor H2	5	175658030-175710756	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013770	Approved					Tissue enhanced	Tissue enhanced		bone marrow: 23.5	appendix: 16.7	Cell line enhanced		RPMI-8226: 45.4;SK-MEL-30: 15.0;THP-1: 12.1;U-937: 16.9
HRH3	GPCR97	ENSG00000101180	Histamine receptor H3	20	62214970-62220267	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	17	cerebral cortex: 11.1	adrenal gland: 0.6	Cell line enriched	7	SCLC-21H: 18.6
HSD3B1	HSD3B, HSDB3, SDR11E1	ENSG00000203857	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	1	119507198-119515054	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043261, HPA043264, HPA044028	Supported				Urothelial cancer:4.59e-5 (favourable)	Tissue enhanced	Tissue enriched	13	placenta: 110.5	small intestine: 8.7	Cell line enriched	7	CACO-2: 52.9
HSD3B2	SDR11E2	ENSG00000203859	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	1	119414931-119423035	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043261, HPA043264, HPA044028	Supported					Tissue enhanced	Tissue enriched	433	adrenal gland: 2384.5	testis: 5.5	Cell line enhanced		SK-MEL-30: 1.2
HTR1A	5-HT1A, ADRB2RL1, ADRBRL1	ENSG00000178394	5-hydroxytryptamine receptor 1A	5	63960356-63962507	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018073	Uncertain					Not detected	Group enriched	10	cerebral cortex: 1.9;ovary: 3.9	testis: 0.2	Group enriched	16	NTERA-2: 1.6;SCLC-21H: 1.5
HTR1B	5-HT1B, 5-HT1DB, HTR1D2, S12	ENSG00000135312	5-hydroxytryptamine receptor 1B	6	77461753-77463773	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028808	Enhanced		Uncertain	Plasma membrane		Mixed	Tissue enhanced		placenta: 10.0;stomach: 4.7	cerebral cortex: 2.4	Group enriched	16	HUVEC TERT2: 68.8;TIME: 29.9
HTR1D	5-HT1D, HT1DA, HTRL, RDC4	ENSG00000179546	5-hydroxytryptamine receptor 1D	1	23191895-23194729	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Liver cancer:1.86e-4 (unfavourable), Pancreatic cancer:5.30e-4 (unfavourable)	Mixed	Group enriched	8	duodenum: 9.4;gallbladder: 2.5;small intestine: 9.1	fallopian tube: 0.9	Cell line enhanced		A549: 9.5;SiHa: 7.5;TIME: 21.6;U-2 OS: 9.0
HTR1E	5-HT1E	ENSG00000168830	5-hydroxytryptamine receptor 1E	6	86937306-87016683	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004931	Approved					Not detected	Tissue enhanced		endometrium: 2.4;ovary: 4.9	cerebral cortex: 1.8	Group enriched	19	PC-3: 1.4;SH-SY5Y: 6.2
HTR1F	5-HT1F, HTR1EL	ENSG00000179097	5-hydroxytryptamine receptor 1F	3	87990696-87993835	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA005555	Uncertain					Not detected	Tissue enhanced		placenta: 2.7	cerebral cortex: 1.0	Cell line enhanced		K-562: 1.1;LHCN-M2: 1.0
HTR2A	5-HT2A, HTR2	ENSG00000102468	5-hydroxytryptamine receptor 2A	13	46831550-46897076	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014011	Enhanced					Not detected	Tissue enriched	8	cerebral cortex: 32.2	smooth muscle: 3.9	Cell line enhanced		ASC diff: 1.3;ASC TERT1: 3.2;BEWO: 1.4;HEL: 1.3;U-138 MG: 2.3;U-2 OS: 1.6
HTR2B	5-HT(2B), 5-HT2B	ENSG00000135914	5-hydroxytryptamine receptor 2B	2	231108230-231125118	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012867, HPA063658	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		cervix, uterine: 31.2;endometrium: 30.1;smooth muscle: 23.2	adrenal gland: 19.1	Cell line enhanced		HHSteC: 7.0;HSkMC: 11.5;SK-MEL-30: 23.9
HTR2C	5-HT2C, 5HTR2C, HTR1C	ENSG00000147246	5-hydroxytryptamine receptor 2C	X	114584078-114910061	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	cerebral cortex: 3.1	cervix, uterine: 0.5	Cell line enhanced		EFO-21: 2.5;U-266/70: 3.6;U-266/84: 2.8
HTR3A	5-HT3A, 5-HT3R, HTR3	ENSG00000166736	5-hydroxytryptamine receptor 3A	11	113974881-113990313	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069442	Supported				Endometrial cancer:1.26e-4 (unfavourable), Cervical cancer:6.26e-4 (favourable)	Tissue enriched	Group enriched	5	appendix: 2.8;lymph node: 7.8;tonsil: 7.2	small intestine: 1.1	Cell line enhanced		CAPAN-2: 5.3;Daudi: 4.2;NTERA-2: 3.6;SCLC-21H: 22.1
HTR3B	5-HT3B	ENSG00000149305	5-hydroxytryptamine receptor 3B	11	113904677-113946565	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039559	Approved					Not detected	Tissue enhanced		cerebral cortex: 2.7	testis: 1.1	Not detected		
HTR3C		ENSG00000178084	5-hydroxytryptamine receptor 3C	3	184053047-184060671	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.9	duodenum: 0.4	Not detected		
HTR3D		ENSG00000186090	5-hydroxytryptamine receptor 3D	3	184031544-184039369	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HTR3E		ENSG00000186038	5-hydroxytryptamine receptor 3E	3	184097064-184106995	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049764	Enhanced					Not detected	Tissue enhanced		duodenum: 1.0	small intestine: 0.8	Cell line enriched	6	RH-30: 1.3
HTR4	5-HT4	ENSG00000164270	5-hydroxytryptamine receptor 4	5	148451032-148677235	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040591	Approved					Not detected	Tissue enhanced		duodenum: 4.8;small intestine: 10.0	rectum: 3.1	Not detected		
HTR6	5-HT6, 5-HT6R	ENSG00000158748	5-hydroxytryptamine receptor 6	1	19665287-19679562	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Not detected			cerebral cortex: 0.8	Cell line enhanced		SH-SY5Y: 2.1
HTR7	5-HT7	ENSG00000148680	5-hydroxytryptamine receptor 7	10	90740823-90857698	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB022708, HPA073617	Approved		Supported	Nuclear speckles<br>Plasma membrane<br>Cytosol		Group enriched	Group enriched	8	parathyroid gland: 44.8;testis: 16.1	urinary bladder: 3.8	Cell line enhanced		hTERT-HME1: 25.8;LHCN-M2: 11.4;WM-115: 12.9
ICAM1	BB2, CD54	ENSG00000090339	Intercellular adhesion molecule 1	19	10270835-10286615	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002126, CAB002142, HPA004877	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			lung: 255.9	Cell line enhanced		Karpas-707: 302.5
IDE		ENSG00000119912	Insulin degrading enzyme	10	92451684-92574076	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA063478	Approved				Endometrial cancer:3.53e-4 (favourable), Colorectal cancer:3.69e-4 (favourable)	Expressed in all	Expressed in all			skin: 63.4	Expressed in all		
IFNAR1	IFNAR, IFRC	ENSG00000142166	Interferon alpha and beta receptor subunit 1	21	33324477-33359862	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018015, HPA029226	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
IFNAR2	IFNABR	ENSG00000159110	Interferon alpha and beta receptor subunit 2	21	33229901-33265675	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.54e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 58.7	Expressed in all		
IFNG		ENSG00000111537	Interferon gamma	12	68154768-68159747	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010344	Approved					Mixed	Tissue enhanced		appendix: 4.7;bone marrow: 7.6;lymph node: 7.9	lung: 2.5	Not detected		
IFNGR1	CD119, IFNGR	ENSG00000027697	Interferon gamma receptor 1	6	137197484-137219449	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025889, HPA063871	Approved				Renal cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 221.9	Expressed in all		
IFNGR2	AF-1, IFNGT1	ENSG00000159128	Interferon gamma receptor 2	21	33402896-33479348	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA001535	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.13e-10 (unfavourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Mixed			spleen: 10.0	Mixed		
IGF1R	CD221, IGFIR, IGFR, JTK13, MGC18216	ENSG00000140443	Insulin like growth factor 1 receptor	15	98648971-98964530	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010268, HPA045563	Uncertain		Uncertain	Vesicles	Renal cancer:3.75e-7 (favourable)	Expressed in all	Mixed			prostate: 25.0	Mixed		
IKBKB	IKK-beta, IKK2, IKKB, NFKBIKB	ENSG00000104365	Inhibitor of nuclear factor kappa B kinase subunit beta	8	42271302-42332653	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001249, CAB004447	Enhanced		Approved	Cytosol	Urothelial cancer:1.46e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.7	Expressed in all		
IL11RA		ENSG00000137070	Interleukin 11 receptor subunit alpha	9	34650702-34661892	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013162, CAB032830, HPA036652	Supported				Renal cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Mixed		
IL12B	CLMF, CLMF2, IL-12B, NKSF, NKSF2	ENSG00000113302	Interleukin 12B	5	159314783-159330887	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040970	Approved					Tissue enriched	Not detected			spleen: 0.6	Cell line enhanced		SCLC-21H: 1.0
IL17A	CTLA8, IL-17, IL-17A, IL17	ENSG00000112115	Interleukin 17A	6	52186387-52190638	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052258	Uncertain					Not detected	Tissue enhanced		appendix: 1.0;tonsil: 1.3;urinary bladder: 1.5	gallbladder: 0.3	Group enriched	16	Karpas-707: 1.9;U-266/84: 1.2
IL1B	IL-1B, IL1-BETA, IL1F2	ENSG00000125538	Interleukin 1 beta	2	112829751-112836903	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 68.0;bone marrow: 106.4	adipose tissue: 53.4	Cell line enhanced		BJ hTERT+: 478.0;HBEC3-KT: 193.4;HMC-1: 189.1;hTEC/SVTERT24-B: 291.2;U-87 MG: 514.6
IL1R1	CD121A, D2S1473, IL1R, IL1RA	ENSG00000115594	Interleukin 1 receptor type 1	2	102064544-102179874	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005823, CAB007779, HPA029560	Approved				Renal cancer:6.92e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 246.0	Cell line enhanced		ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6
IL23A	IL-23, IL-23A, IL23P19, P19, SGRF	ENSG00000110944	Interleukin 23 subunit alpha	12	56334174-56340410	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA001554	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		tonsil: 8.0	urinary bladder: 6.5	Cell line enhanced		A-431: 13.0;CAPAN-2: 22.3;U-266/70: 31.8;U-266/84: 14.0
IL2RA	CD25, IDDM10, IL2R	ENSG00000134460	Interleukin 2 receptor subunit alpha	10	6010689-6062325	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002419, HPA054622	Enhanced				Renal cancer:2.08e-9 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 24.2;appendix: 19.8;lymph node: 20.4	tonsil: 12.0	Cell line enriched	80	HDLM-2: 1041.6
IL2RB	CD122, IL15RB	ENSG00000100385	Interleukin 2 receptor subunit beta	22	37125838-37175054	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062657	Enhanced				Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 52.7;spleen: 67.1	lymph node: 39.8	Cell line enriched	10	HDLM-2: 476.9
IL2RG	CD132, CIDX, IMD4, SCIDX1	ENSG00000147168	Interleukin 2 receptor subunit gamma	X	71107404-71112108	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046641, HPA049691	Enhanced		Approved	Vesicles	Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 273.3;tonsil: 279.4	appendix: 182.3	Cell line enriched	5	Karpas-707: 1646.4
IL3RA	CD123	ENSG00000185291	Interleukin 3 receptor subunit alpha	X	1336616-1382689	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003539, CAB018374	Approved				Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HDLM-2: 109.2;RPMI-8226: 33.2
IL5	EDF, IL-5, TRF	ENSG00000113525	Interleukin 5	5	132541444-132556838	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010304	Approved					Not detected	Tissue enriched	9	testis: 9.6	small intestine: 1.0	Cell line enhanced		Hep G2: 1.9;TIME: 1.0
IL6	BSF2, HGF, HSF, IFNB2, IL-6	ENSG00000136244	Interleukin 6	7	22725884-22732002	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB023406, CAB072821	Supported		Approved	Vesicles	Renal cancer:1.10e-11 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 136.4	urinary bladder: 73.6	Group enriched	7	BJ hTERT+: 1844.6;hTEC/SVTERT24-B: 429.5
IL6R	CD126	ENSG00000160712	Interleukin 6 receptor	1	154405193-154469450	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.65e-4 (favourable)	Expressed in all	Mixed			appendix: 33.4	Cell line enhanced		THP-1: 147.4;U-266/84: 186.8
IMPDH1	LCA11, RP10, sWSS2608	ENSG00000106348	Inosine monophosphate dehydrogenase 1	7	128392277-128410252	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001400	Approved		Supported	Cytosol<br>Rods & Rings	Renal cancer:1.78e-12 (unfavourable), Liver cancer:1.12e-7 (unfavourable), Urothelial cancer:3.72e-5 (unfavourable), Glioma:1.17e-4 (unfavourable), Cervical cancer:3.87e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 47.2	Expressed in all		
IMPDH2		ENSG00000178035	Inosine monophosphate dehydrogenase 2	3	49024325-49029408	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001400, CAB020717	Approved		Enhanced	Cytosol<br>Rods & Rings	Liver cancer:3.22e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 422.5	Expressed in all		
INSR	CD220	ENSG00000171105	Insulin receptor	19	7112255-7294034	CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA036302, HPA036303	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			ovary: 35.5	Cell line enhanced		Karpas-707: 42.9
ITGA2B	CD41, CD41B, GP2B, PPP1R93	ENSG00000005961	Integrin subunit alpha 2b	17	44372180-44389505	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018611, HPA031168, HPA031169, HPA031170, HPA031171	Enhanced					Mixed	Tissue enhanced		bone marrow: 11.2;epididymis: 29.3	testis: 4.4	Group enriched	18	HEL: 396.8;HMC-1: 636.9
ITGA4	CD49D	ENSG00000115232	Integrin subunit alpha 4	2	181457202-181536187	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074961			Approved	Plasma membrane	Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable)	Mixed	Tissue enhanced		spleen: 67.6	appendix: 49.6	Cell line enhanced		fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
ITGAL	CD11A, LFA-1	ENSG00000005844	Integrin subunit alpha L	16	30472658-30523185	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025011	Enhanced				Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 79.0;spleen: 80.9	appendix: 52.5	Cell line enriched	5	HMC-1: 570.1
ITGAV	CD51, MSK8, VNRA, VTNR	ENSG00000138448	Integrin subunit alpha V	2	186590065-186680901	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002499, HPA004856	Supported		Approved	Focal adhesion sites<br>Cytosol	Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 191.2	Cell line enhanced		RT4: 294.1
ITGB1	CD29, FNRB, GPIIA, MDF2, MSK12	ENSG00000150093	Integrin subunit beta 1	10	32900319-33005792	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB003434, HPA059297, HPA069003	Enhanced		Supported	Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites	Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1069.5	Expressed in all		
ITGB3	CD61, GP3A, GPIIIa	ENSG00000259207	Integrin subunit beta 3	17	47253846-47311816	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027852	Supported					Group enriched	Tissue enhanced		thyroid gland: 95.6	smooth muscle: 36.8	Cell line enhanced		EFO-21: 179.0;HEL: 158.0;WM-115: 275.8
ITGB7		ENSG00000139626	Integrin subunit beta 7	12	53191318-53207307	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042277			Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			spleen: 32.5	Group enriched	97	Karpas-707: 3399.5;RPMI-8226: 2658.1
JAK1	JAK1A, JAK1B, JTK3	ENSG00000162434	Janus kinase 1	1	64833229-64966504	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013088	Approved				Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 115.6	Expressed in all		
JAK2	JTK10	ENSG00000096968	Janus kinase 2	9	4984390-5128183	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013089, HPA040820, HPA043870	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Expressed in all	Mixed			appendix: 28.1	Group enriched	6	ASC diff: 34.8;HDLM-2: 71.3;HEL: 140.3
JAK3	JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK	ENSG00000105639	Janus kinase 3	19	17824780-17848071	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA070314	Enhanced				Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 48.4;lymph node: 46.6	tonsil: 27.2	Cell line enhanced		HDLM-2: 33.0;Karpas-707: 28.7;U-266/84: 17.1;U-937: 18.8
JUN	AP-1, c-Jun	ENSG00000177606	Jun proto-oncogene, AP-1 transcription factor subunit	1	58780788-58784327	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003801, CAB007780, HPA059474	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 314.6	Cell line enhanced		RH-30: 282.2
KCNA1	AEMK, HUK1, Kv1.1, MBK1, RBK1	ENSG00000111262	Potassium voltage-gated channel subfamily A member 1	12	4909893-4918256	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB022365	Uncertain					Not detected	Tissue enriched	6	cerebral cortex: 13.4	parathyroid gland: 2.1	Cell line enhanced		SCLC-21H: 1.2;U-2 OS: 1.0
KCNA10	Kv1.8	ENSG00000143105	Potassium voltage-gated channel subfamily A member 10	1	110517217-110519175	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA015061, CAB022564			Uncertain	Nucleoplasm<br>Cytosol		Not detected	Not detected			testis: 0.8	Not detected		
KCNA2	HK4, Kv1.2	ENSG00000177301	Potassium voltage-gated channel subfamily A member 2	1	110519837-110631474	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB001976	Enhanced					Tissue enhanced	Tissue enriched	6	cerebral cortex: 23.2	thyroid gland: 4.1	Cell line enhanced		Karpas-707: 4.4;SCLC-21H: 1.8;U-2 OS: 1.4;U-266/70: 1.5;U-266/84: 2.3;WM-115: 1.6
KCNA3	HLK3, HPCN3, Kv1.3, MK3	ENSG00000177272	Potassium voltage-gated channel subfamily A member 3	1	110672465-110675033	FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016625	Approved					Mixed	Mixed			lymph node: 10.5	Cell line enhanced		HDLM-2: 20.5;Karpas-707: 31.5;U-266/70: 23.9;U-266/84: 21.1
KCNA4	HK1, HPCN2, KCNA4L, Kv1.4	ENSG00000182255	Potassium voltage-gated channel subfamily A member 4	11	30009741-30017023	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB001977, HPA016422	Approved					Not detected	Tissue enhanced		adrenal gland: 7.9;cerebral cortex: 4.3	heart muscle: 1.4	Not detected		
KCNA5	HK2, HPCN1, Kv1.5	ENSG00000130037	Potassium voltage-gated channel subfamily A member 5	12	5043989-5046788	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA021516, CAB022562	Approved					Mixed	Tissue enhanced		heart muscle: 16.1	esophagus: 5.6	Cell line enriched	20	NTERA-2: 4.3
KCNA6	HBK2, Kv1.6, PPP1R96	ENSG00000151079	Potassium voltage-gated channel subfamily A member 6	12	4809176-4813412	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	CAB011539, HPA014418	Approved					Not detected	Not detected			appendix,duodenum,lymph node: 0.1	Not detected		
KCNA7	HAK6, Kv1.7	ENSG00000104848	Potassium voltage-gated channel subfamily A member 7	19	49067418-49072941	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level							Not detected	Tissue enriched	37	skeletal muscle: 26.2	esophagus: 0.7	Not detected		
KCNB1	Kv2.1	ENSG00000158445	Potassium voltage-gated channel subfamily B member 1	20	49293394-49484297	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB001979, HPA042434	Enhanced					Mixed	Tissue enhanced		adipose tissue: 10.9;cerebral cortex: 21.6	fallopian tube,smooth muscle: 7.4	Cell line enhanced		CACO-2: 1.8;U-2 OS: 1.8
KCNB2	Kv2.2	ENSG00000182674	Potassium voltage-gated channel subfamily B member 2	8	72537391-72938349	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA065970			Approved	Nucleoli<br>Plasma membrane<br>Midbody		Not detected	Tissue enhanced		cerebral cortex: 3.2;spleen: 3.3	fallopian tube,testis: 0.7	Cell line enhanced		HaCaT: 1.3;HDLM-2: 1.4;HEK93: 3.2;SCLC-21H: 3.4
KCNC1	Kv3.1	ENSG00000129159	Potassium voltage-gated channel subfamily C member 1	11	17734774-17856804	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA047634, HPA048249	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol		Tissue enhanced	Tissue enriched	8	cerebral cortex: 18.6	testis: 2.2	Cell line enhanced		RH-30: 3.6;SCLC-21H: 4.2;SH-SY5Y: 2.3
KCNC2	Kv3.2	ENSG00000166006	Potassium voltage-gated channel subfamily C member 2	12	75040077-75209868	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA019664, CAB022571	Uncertain		Supported	Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	11	cerebral cortex: 46.4	prostate: 4.3	Not detected		
KCNC3	Kv3.3, SCA13	ENSG00000131398	Potassium voltage-gated channel subfamily C member 3	19	50311937-50333515	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018041	Approved				Renal cancer:1.23e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 39.9	cerebral cortex: 19.8	Cell line enhanced		HMC-1: 26.4;SK-BR-3: 15.3;T-47d: 18.4;U-2 OS: 13.8
KCND1	Kv4.1	ENSG00000102057	Potassium voltage-gated channel subfamily D member 1	X	48961378-48971569	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA000524, HPA001066	Approved		Approved	Nucleus	Pancreatic cancer:2.66e-6 (favourable)	Mixed	Mixed			gallbladder: 3.9	Mixed		
KCND2	KIAA1044, Kv4.2, RK5	ENSG00000184408	Potassium voltage-gated channel subfamily D member 2	7	120273668-120750331	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029068	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 20.7	gallbladder: 6.8	Cell line enhanced		ASC TERT1: 3.5;SCLC-21H: 15.6
KCND3	KSHIVB, Kv4.3, SCA19, SCA22	ENSG00000171385	Potassium voltage-gated channel subfamily D member 3	1	111770662-111989155	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029452	Approved					Mixed	Mixed			cerebral cortex: 26.7	Cell line enhanced		SCLC-21H: 14.0;WM-115: 2.8
KCNE1	ISK, JLNS2, LQT5, minK	ENSG00000180509	Potassium voltage-gated channel subfamily E regulatory subunit 1	21	34446688-34512275	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 16.6	heart muscle: 3.6	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1.2;CACO-2: 3.3
KCNH2	erg1, HERG, Kv11.1, LQT2	ENSG00000055118	Potassium voltage-gated channel subfamily H member 2	7	150944961-150978315	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Endometrial cancer:6.06e-5 (unfavourable), Pancreatic cancer:5.61e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 24.1;testis: 27.3	parathyroid gland: 13.2	Group enriched	6	K-562: 170.9;NB-4: 59.5;SH-SY5Y: 79.9
KCNJ1	Kir1.1, ROMK1	ENSG00000151704	Potassium voltage-gated channel subfamily J member 1	11	128836315-128867373	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA026962	Enhanced					Tissue enriched	Tissue enriched	117	kidney: 210.8	epididymis: 1.7	Cell line enriched	42	RPTEC TERT1: 87.0
KCNJ11	BIR, Kir6.2	ENSG00000187486	Potassium voltage-gated channel subfamily J member 11	11	17385859-17389331	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA048891	Approved				Renal cancer:1.56e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 32.7	cerebral cortex: 10.2	Cell line enhanced		HEK93: 12.0;MCF7: 8.2;SCLC-21H: 10.3
KCNJ12	hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v	ENSG00000184185	Potassium voltage-gated channel subfamily J member 12	17	21376197-21419872	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA027021	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:7.84e-5 (unfavourable)	Mixed	Group enriched	5	parathyroid gland: 19.2;skeletal muscle: 23.1	heart muscle: 3.9	Cell line enhanced		HeLa: 2.6;PC-3: 3.9;SCLC-21H: 5.6;SiHa: 2.6;U-2197: 3.9
KCNJ8	Kir6.1	ENSG00000121361	Potassium voltage-gated channel subfamily J member 8	12	21764955-21775581	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA031066	Uncertain				Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 32.0	Cell line enhanced		CACO-2: 71.9;SH-SY5Y: 31.1
KCNK2	K2p2.1, TREK-1	ENSG00000082482	Potassium two pore domain channel subfamily K member 2	1	215005775-215237093	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 75.2	thyroid gland: 17.0	Cell line enhanced		ASC TERT1: 58.1;fHDF/TERT166: 59.9;T-47d: 108.4;U-2197: 38.1
KCNK3	K2p3.1, TASK, TASK-1	ENSG00000171303	Potassium two pore domain channel subfamily K member 3	2	26692690-26733420	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Renal cancer:2.37e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 111.8;placenta: 35.8	lung: 19.9	Group enriched	6	EFO-21: 10.3;SCLC-21H: 30.6
KCNK9	K2p9.1, TASK-3, TASK3	ENSG00000169427	Potassium two pore domain channel subfamily K member 9	8	139600838-139703056	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Group enriched	7	adrenal gland: 4.7;cerebral cortex: 4.8	cervix, uterine: 0.7	Cell line enhanced		PC-3: 2.0;SCLC-21H: 1.1
KCNMA1	KCa1.1, mSLO1, SLO	ENSG00000156113	Potassium calcium-activated channel subfamily M alpha 1	10	76869601-77638369	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA054648	Approved					Mixed	Tissue enhanced		smooth muscle: 137.0	endometrium: 109.5	Cell line enhanced		PC-3: 148.0;U-138 MG: 111.0;U-87 MG: 107.5
KCNN4	hIKCa1, hKCa4, hSK4, IK, KCa3.1	ENSG00000104783	Potassium calcium-activated channel subfamily N member 4	19	43766533-43781257	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA053841, HPA059622	Approved				Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 73.7	stomach: 36.6	Cell line enhanced		CAPAN-2: 93.3;WM-115: 264.9
KCNQ1	JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1	ENSG00000053918	Potassium voltage-gated channel subfamily Q member 1	11	2444684-2849109	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB018656, HPA048553	Enhanced				Stomach cancer:9.85e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 133.6;thyroid gland: 102.7	seminal vesicle: 60.6	Cell line enhanced		HMC-1: 25.7;RPMI-8226: 14.2;U-266/70: 8.9;U-937: 8.8
KCNQ2	BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2	ENSG00000075043	Potassium voltage-gated channel subfamily Q member 2	20	63400210-63472677	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016642, HPA057112	Enhanced		Approved	Endoplasmic reticulum		Tissue enriched	Tissue enriched	7	cerebral cortex: 57.2	testis: 8.2	Cell line enhanced		AN3-CA: 32.4;SCLC-21H: 79.6;SH-SY5Y: 126.1
KCNQ3	EBN2, Kv7.3	ENSG00000184156	Potassium voltage-gated channel subfamily Q member 3	8	132120858-132481019	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	14	cerebral cortex: 26.7	adrenal gland: 1.9	Cell line enhanced		hTERT-HME1: 5.1;U-2 OS: 4.5;U-87 MG: 3.5
KDR	CD309, FLK1, VEGFR, VEGFR2	ENSG00000128052	Kinase insert domain receptor	4	55078477-55125589	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB004028	Enhanced		Supported	Plasma membrane	Renal cancer:7.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 119.2	thyroid gland: 54.7	Group enriched	9	HUVEC TERT2: 178.6;TIME: 148.0
KEAP1	INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454	ENSG00000079999	Kelch like ECH associated protein 1	19	10486120-10503741	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005558, CAB025337	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Cervical cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 49.4	Expressed in all		
KIT	C-Kit, CD117, PBT, SCFR	ENSG00000157404	KIT proto-oncogene receptor tyrosine kinase	4	54657918-54740715	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB003288, HPA004471, CAB068253, CAB072867, HPA073252	Enhanced	Supported	Supported	Plasma membrane	Renal cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced		breast: 133.6	thyroid gland: 78.7	Group enriched	14	HEL: 220.1;HMC-1: 434.1
KLKB1	KLK3	ENSG00000164344	Kallikrein B1	4	186208979-186258471	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	45	liver: 155.0	gallbladder,kidney: 3.4	Cell line enhanced		NTERA-2: 2.9;SCLC-21H: 2.3
LCK		ENSG00000182866	LCK proto-oncogene, Src family tyrosine kinase	1	32251239-32286165	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003494, CAB003816	Enhanced		Approved	Golgi apparatus	Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 125.9;tonsil: 72.4	appendix: 66.3	Group enriched	7	MOLT-4: 429.5;U-698: 207.6
LEPR	CD295, OBR	ENSG00000116678	Leptin receptor	1	65420652-65641559	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA030899	Approved		Approved	Vesicles		Tissue enriched	Mixed			liver: 67.9	Cell line enhanced		K-562: 102.4;RPTEC TERT1: 39.6
LHCGR	HHG, LCGR, LGR2, LHR, ULG5	ENSG00000138039	Luteinizing hormone/choriogonadotropin receptor	2	48686775-48755730	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009814	Uncertain					Not detected	Tissue enhanced		ovary: 1.6;testis: 4.3	adipose tissue: 1.3	Not detected		
LIPF	HGL, HLAL	ENSG00000182333	Lipase F, gastric type	10	88664441-88678814	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA045930	Enhanced					Tissue enriched	Tissue enriched	86	stomach: 22415.5	duodenum: 259.5	Cell line enhanced		HMC-1: 3.6;MOLT-4: 2.7;NTERA-2: 3.5;THP-1: 4.5;U-2 OS: 2.4;U-266/70: 2.4
LPL	LIPD	ENSG00000175445	Lipoprotein lipase	8	19901717-19967258	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048749			Supported	Vesicles	Urothelial cancer:6.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 976.8	heart muscle: 239.2	Cell line enriched	7	AF22: 363.8
M6PR	CD-M6PR, CD-MPR	ENSG00000003056	Mannose-6-phosphate receptor, cation dependent	12	8940363-8949955	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034464, HPA040445	Approved				Liver cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 175.3	Expressed in all		
MAOA		ENSG00000189221	Monoamine oxidase A	X	43654907-43746824	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB009437, HPA054807, HPA059299	Enhanced		Enhanced	Mitochondria		Expressed in all	Mixed			small intestine: 248.3	Cell line enhanced		ASC diff: 108.7;HHSteC: 249.1;hTCEpi: 61.9;RT4: 102.5
MAOB		ENSG00000069535	Monoamine oxidase B	X	43766611-43882447	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA002328, CAB037200	Enhanced		Approved	Nucleoli<br>Mitochondria		Expressed in all	Mixed			seminal vesicle: 215.4	Group enriched	9	Hep G2: 28.1;SiHa: 82.8
MAP1A	MAP1L	ENSG00000166963	Microtubule associated protein 1A	15	43510958-43531620	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039063, HPA039064, HPA066488	Enhanced		Approved	Cytosol	Thyroid cancer:1.09e-5 (unfavourable), Urothelial cancer:1.66e-5 (unfavourable), Renal cancer:6.59e-5 (unfavourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 165.6	smooth muscle: 18.9	Cell line enhanced		fHDF/TERT166: 72.9;U-87 MG: 119.0
MAP2	MAP2A, MAP2B, MAP2C	ENSG00000078018	Microtubule associated protein 2	2	209424058-209734118	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001984, HPA008273, HPA012828	Enhanced	Supported	Supported	Nucleoli<br>Cytosol	Endometrial cancer:1.98e-6 (unfavourable)	Tissue enhanced	Tissue enriched	11	cerebral cortex: 296.5	thyroid gland: 27.9	Cell line enhanced		AF22: 293.3;NTERA-2: 106.5;SCLC-21H: 174.9;SH-SY5Y: 88.2
MAP2K1	MAPKK1, MEK1, PRKMK1	ENSG00000169032	Mitogen-activated protein kinase kinase 1	15	66386817-66492312	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003834, HPA026430	Approved		Enhanced	Plasma membrane<br>Cytosol	Glioma:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.4	Expressed in all		
MAP2K2	MEK2, PRKMK2	ENSG00000126934	Mitogen-activated protein kinase kinase 2	19	4090321-4124129	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003835, HPA051993	Supported		Supported	Cytosol	Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 135.0	Expressed in all		
MAP4		ENSG00000047849	Microtubule associated protein 4	3	47850690-48089272	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038149, HPA038150	Enhanced		Supported	Plasma membrane<br>Microtubules<br>Cytosol	Liver cancer:1.82e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 241.9	Expressed in all		
MAPK1	ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2	ENSG00000100030	Mitogen-activated protein kinase 1	22	21754500-21867680	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003995, CAB004229, HPA005700, HPA030069	Approved				Liver cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.4	Expressed in all		
MAPK11	p38-2, p38Beta, PRKM11, SAPK2	ENSG00000185386	Mitogen-activated protein kinase 11	22	50263713-50270767	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB012961, HPA045069	Approved		Approved	Mitochondria	Renal cancer:6.02e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 27.7	Mixed		
MAPK3	ERK1, p44erk1, p44mapk, PRKM3	ENSG00000102882	Mitogen-activated protein kinase 3	16	30114105-30123506	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002683, HPA003995, HPA005700, HPA030069	Approved		Approved	Nucleoplasm	Liver cancer:1.11e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 133.7	Expressed in all		
MAPT	DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau	ENSG00000186868	Microtubule associated protein tau	17	45894382-46028334	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000151, HPA048895, HPA069524, HPA069570, CAB072344	Enhanced		Supported	Nuclear speckles<br>Plasma membrane		Group enriched	Tissue enriched	8	cerebral cortex: 116.2	skeletal muscle: 13.7	Cell line enhanced		HDLM-2: 37.4;SCLC-21H: 16.3;T-47d: 16.5
MC2R	ACTHR	ENSG00000185231	Melanocortin 2 receptor	18	13882044-13915707	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	23	adrenal gland: 50.6	epididymis: 2.1	Not detected		
MET	DFNB97, HGFR, RCCP2	ENSG00000105976	MET proto-oncogene, receptor tyrosine kinase	7	116672390-116798386	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005282, CAB018577, HPA055607	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.0	Mixed		
METAP2	MAP2, MNPEP, p67	ENSG00000111142	Methionyl aminopeptidase 2	12	95473520-95515839	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013025, HPA019095	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.51e-6 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 142.4	Expressed in all		
MGAM	MGA	ENSG00000257335	Maltase-glucoamylase	7	141907813-142106747	Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002270	Enhanced				Renal cancer:6.16e-5 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 59.4;small intestine: 97.2	epididymis: 31.1	Cell line enhanced		A549: 1.6;BJ hTERT+: 1.3;HL-60: 2.2;U-937: 3.4
MME	CALLA, CD10, NEP	ENSG00000196549	Membrane metalloendopeptidase	3	155024124-155183729	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000013, HPA052583, HPA056072	Enhanced					Mixed	Tissue enhanced		duodenum: 428.2;kidney: 384.2;small intestine: 401.5	prostate: 162.5	Cell line enhanced		ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
MMP1	CLG	ENSG00000196611	Matrix metallopeptidase 1	11	102789920-102798160	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004920			Approved	Vesicles	Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 39.2;gallbladder: 126.4	urinary bladder: 29.1	Cell line enhanced		BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
MMP10	STMY2	ENSG00000166670	Matrix metallopeptidase 10	11	102770503-102780628	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB002159	Uncertain		Approved	Plasma membrane<br>Cytosol	Urothelial cancer:7.12e-4 (favourable)	Tissue enhanced	Tissue enriched	40	endometrium: 443.1	appendix: 11.1	Cell line enhanced		BJ: 10.0;HUVEC TERT2: 12.6;SCLC-21H: 5.6
MMP11	STMY3	ENSG00000099953	Matrix metallopeptidase 11	22	23768226-23784316	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB002593, HPA068864	Approved				Renal cancer:2.62e-4 (unfavourable)	Expressed in all	Group enriched	9	cervix, uterine: 31.6;endometrium: 123.1;placenta: 28.0	smooth muscle: 6.9	Cell line enhanced		AN3-CA: 17.4;REH: 7.4
MMP12	HME	ENSG00000262406	Matrix metallopeptidase 12	11	102862736-102875034	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level						Liver cancer:1.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 54.6;urinary bladder: 28.7	tonsil: 17.3	Group enriched	11	BJ: 2.7;fHDF/TERT166: 8.5;hTEC/SVTERT24-B: 6.1
MMP13	CLG3	ENSG00000137745	Matrix metallopeptidase 13	11	102942995-102955734	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		lung: 1.5;urinary bladder: 1.3	appendix: 0.3	Cell line enhanced		HaCaT: 15.8;PC-3: 6.2
MMP14	MT1-MMP	ENSG00000157227	Matrix metallopeptidase 14	14	22836557-22849027	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009918, HPA051432	Approved		Approved	Intermediate filaments<br>Cytosol	Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 236.6	Cell line enhanced		HHSteC: 664.7
MMP15	MT2-MMP, MTMMP2, SMCP-2	ENSG00000102996	Matrix metallopeptidase 15	16	58025566-58046901	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002611, HPA040390	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 70.1	placenta: 39.3	Cell line enhanced		BEWO: 86.0;WM-115: 73.7
MMP16	C8orf57, DKFZp761D112, MT3-MMP	ENSG00000156103	Matrix metallopeptidase 16	8	88032009-88328025	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023693	Uncertain		Approved	Vesicles<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 9.6	gallbladder: 4.2	Cell line enhanced		AN3-CA: 27.2;SH-SY5Y: 17.2;WM-115: 28.4
MMP17	MT4-MMP	ENSG00000198598	Matrix metallopeptidase 17	12	131828393-131851783	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		cerebral cortex: 24.0	skin: 8.2	Group enriched	5	REH: 53.0;SK-MEL-30: 109.1;WM-115: 201.0
MMP19	MMP18, RASI-1	ENSG00000123342	Matrix metallopeptidase 19	12	55835433-55842966	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA070804			Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:8.56e-9 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 64.2;gallbladder: 97.3	placenta: 28.2	Cell line enriched	7	BEWO: 141.1
MMP2	CLG4, CLG4A, TBE-1	ENSG00000087245	Matrix metallopeptidase 2	16	55389700-55506691	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001939, CAB002788	Approved		Uncertain	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		gallbladder: 1682.1	urinary bladder: 910.7	Cell line enhanced		ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5
MMP20		ENSG00000137674	Matrix metallopeptidase 20	11	102576835-102625332	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.1	appendix,breast,kidney,tonsil: 0.1	Not detected		
MMP21		ENSG00000154485	Matrix metallopeptidase 21	10	125766453-125775821	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	27	epididymis: 59.2	ovary: 2.1	Not detected		
MMP23B	MIFR, MIFR-1, MMP22	ENSG00000189409	Matrix metallopeptidase 23B	1	1632095-1635263	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Mixed			gallbladder,placenta: 4.1	Cell line enhanced		HHSteC: 3.5;NTERA-2: 1.8;U-266/70: 2.5
MMP24	MT5-MMP	ENSG00000125966	Matrix metallopeptidase 24	20	35226654-35277000	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA049280			Approved	Nucleoli<br>Plasma membrane	Renal cancer:8.17e-11 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 10.6	lung: 7.0	Cell line enhanced		A549: 32.8;CACO-2: 46.1;RPTEC TERT1: 18.5;U-2 OS: 18.9
MMP25	MMP20, MMPL1, MT6-MMP	ENSG00000008516	Matrix metallopeptidase 25	16	3046681-3060726	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025177	Uncertain				Head and neck cancer:1.09e-5 (favourable)	Tissue enhanced	Tissue enhanced		appendix: 23.3;bone marrow: 24.7;spleen: 20.7	adipose tissue: 6.4	Cell line enriched	11	HMC-1: 95.7
MMP26	endometase, MGC126590, MGC126592	ENSG00000167346	Matrix metallopeptidase 26	11	4704927-4992429	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enriched	63	endometrium: 23.9	prostate,testis: 0.3	Not detected		
MMP27		ENSG00000137675	Matrix metallopeptidase 27	11	102691487-102705806	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA069097	Approved					Not detected	Group enriched	5	breast: 6.0;skin: 2.8	bone marrow: 0.8	Not detected		
MMP28	EPILYSIN, MM28, MMP-25, MMP-28	ENSG00000271447	Matrix metallopeptidase 28	17	35756249-35795707	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:6.28e-6 (unfavourable)	Mixed	Tissue enhanced		testis: 6.5	adipose tissue: 4.2	Cell line enriched	9	HaCaT: 32.1
MMP3	STMY, STMY1	ENSG00000149968	Matrix metallopeptidase 3	11	102835801-102843803	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007875	Uncertain		Supported	Vesicles	Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 26.5;endometrium: 58.6	urinary bladder: 9.0	Group enriched	15	BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8
MMP7	MPSL1, PUMP-1	ENSG00000137673	Matrix metallopeptidase 7	11	102520508-102530753	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025869, HPA051358	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 820.8	breast: 201.7	Cell line enhanced		A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4
MMP8	CLG1	ENSG00000118113	Matrix metallopeptidase 8	11	102711795-102727050	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021221, HPA022935	Enhanced					Tissue enriched	Tissue enriched	103	bone marrow: 335.8	endometrium: 3.2	Cell line enriched	10	WM-115: 69.6
MMP9	CLG4B	ENSG00000100985	Matrix metallopeptidase 9	20	46008908-46016561	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201	Enhanced		Approved	Cytosol	Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 252.6;lymph node: 117.7	appendix: 82.8	Cell line enriched	8	NB-4: 227.3
MPL	CD110, TPOR	ENSG00000117400	MPL proto-oncogene, thrombopoietin receptor	1	43337849-43352772	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			ovary: 1.3	Cell line enriched	97	HEL: 51.8
MR1	HLALS	ENSG00000153029	Major histocompatibility complex, class I-related	1	181033425-181061938	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048304			Supported	Plasma membrane		Expressed in all	Mixed			thyroid gland: 28.2	Mixed		
MS4A1	B1, Bp35, CD20, MS4A2	ENSG00000156738	Membrane spanning 4-domains A1	11	60455752-60470760	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000015, HPA014341, HPA014391	Enhanced		Supported	Plasma membrane	Breast cancer:4.34e-5 (favourable)	Mixed	Group enriched	15	appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8	urinary bladder: 38.3	Group enriched	19	Daudi: 534.8;U-698: 258.0
MS4A2	APY, FCER1B, IGER, MS4A1	ENSG00000149534	Membrane spanning 4-domains A2	11	60088261-60098466	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA059967	Enhanced					Mixed	Tissue enhanced		lung: 24.8	gallbladder: 18.4	Cell line enhanced		HEL: 2.4;THP-1: 1.0
MTNR1A	MEL-1A-R	ENSG00000168412	Melatonin receptor 1A	4	186533655-186555567	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		kidney: 2.2;testis: 1.9	colon: 1.2	Not detected		
MTNR1B		ENSG00000134640	Melatonin receptor 1B	11	92969720-92985066	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		placenta: 1.4	testis: 0.8	Not detected		
MTOR	FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1	ENSG00000198793	Mechanistic target of rapamycin	1	11106535-11262507	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB069425, HPA071227	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.49e-5 (favourable)	Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
MTR	cblG	ENSG00000116984	5-methyltetrahydrofolate-homocysteine methyltransferase	1	236795281-236903981	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044474, HPA054915	Approved		Supported	Cytosol	Thyroid cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
MTTP	ABL, MTP	ENSG00000138823	Microsomal triglyceride transfer protein	4	99563761-99623999	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051170, HPA054862	Uncertain		Approved	Cytosol		Tissue enriched	Group enriched	16	duodenum: 236.3;liver: 133.9;small intestine: 292.6	testis: 13.5	Cell line enhanced		AF22: 10.2;Hep G2: 8.0
MUT		ENSG00000146085	Methylmalonyl-CoA mutase	6	49430360-49463191	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035971, HPA035972	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:8.71e-13 (favourable)	Expressed in all	Expressed in all			liver: 104.1	Expressed in all		
NFKB1	KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50	ENSG00000109320	Nuclear factor kappa B subunit 1	4	102501329-102617302	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004031, HPA027305	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 56.9	Expressed in all		
NISCH	I-1, IRAS, KIAA0975	ENSG00000010322	Nischarin	3	52455118-52493071	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023189	Approved				Pancreatic cancer:1.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 96.0	Expressed in all		
NNMT		ENSG00000166741	Nicotinamide N-methyltransferase	11	114257787-114313285	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059180	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.02e-6 (unfavourable), Stomach cancer:1.75e-4 (unfavourable), Head and neck cancer:2.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 197.2	adipose tissue: 107.8	Cell line enhanced		HSkMC: 300.0;RPTEC TERT1: 491.7
NOS2	HEP-NOS, iNOS, NOS, NOS2A	ENSG00000007171	Nitric oxide synthase 2	17	27756766-27800499	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002014	Approved					Tissue enhanced	Group enriched	5	appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5	smooth muscle: 2.5	Group enriched	8	CACO-2: 13.0;SCLC-21H: 14.7
NOS3	ECNOS, eNOS	ENSG00000164867	Nitric oxide synthase 3	7	150990995-151014588	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002168	Enhanced				Renal cancer:3.63e-4 (unfavourable)	Expressed in all	Tissue enriched	7	spleen: 71.8	adipose tissue: 10.6	Cell line enhanced		BEWO: 22.3;HUVEC TERT2: 37.6;TIME: 67.7
NOXO1	P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28	ENSG00000196408	NADPH oxidase organizer 1	16	1978917-1984192	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071540	Enhanced					Not detected	Tissue enhanced		appendix: 6.3;colon: 7.4;rectum: 6.5	duodenum: 3.3	Cell line enhanced		CAPAN-2: 2.4;HaCaT: 1.4;SCLC-21H: 1.6
NPC1L1		ENSG00000015520	NPC1 like intracellular cholesterol transporter 1	7	44512535-44541315	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB070127, CAB070128	Enhanced					Group enriched	Tissue enhanced		duodenum: 57.1;small intestine: 57.9	liver: 14.2	Group enriched	7	CACO-2: 5.9;Hep G2: 12.2;SCLC-21H: 17.4
NPR1	ANPa, ANPRA, GUCY2A, NPRA	ENSG00000169418	Natriuretic peptide receptor 1	1	153678637-153693992	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA031087			Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 72.0;fallopian tube: 58.2	placenta: 25.4	Cell line enriched	6	ASC diff: 107.2
NPR2	AMDM, ANPb, ANPRB, GUCY2B, NPRB	ENSG00000159899	Natriuretic peptide receptor 2	9	35792154-35809732	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Expressed in all	Mixed			endometrium: 31.1	Cell line enhanced		ASC diff: 37.7
NR1H4	FXR, HRR-1, HRR1, RIP14	ENSG00000012504	Nuclear receptor subfamily 1 group H member 4	12	100473708-100564413	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	HPA047699			Approved	Nucleoplasm		Group enriched	Tissue enhanced		liver: 66.6;small intestine: 44.4	kidney: 29.9	Group enriched	26	Hep G2: 20.2;HHSteC: 14.1;RPTEC TERT1: 34.8
NR1I2	BXR, ONR1, PAR2, PXR, SXR	ENSG00000144852	Nuclear receptor subfamily 1 group I member 2	3	119780484-119818485	FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029309, HPA055121, HPA073926			Enhanced	Nucleoplasm		Group enriched	Group enriched	10	colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0	stomach: 1.7	Group enriched	7	Hep G2: 9.8;RH-30: 3.3
NR3C1	GR, GRL	ENSG00000113580	Nuclear receptor subfamily 3 group C member 1	5	143277931-143435512	Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004248, CAB010435	Supported		Enhanced	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.72e-6 (unfavourable), Endometrial cancer:3.64e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 67.0	Mixed		
NR3C2	MLR, MR	ENSG00000151623	Nuclear receptor subfamily 3 group C member 2	4	148078762-148444698	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009155, HPA074979	Enhanced		Supported	Nucleoplasm	Renal cancer:3.10e-11 (favourable)	Mixed	Mixed			thyroid gland: 32.3	Cell line enhanced		HUVEC TERT2: 4.9;Karpas-707: 4.5;PC-3: 5.4;RPTEC TERT1: 5.9;TIME: 6.4
NTRK1	MTC, TRK, TRKA	ENSG00000198400	Neurotrophic receptor tyrosine kinase 1	1	156815640-156881850	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004606, HPA035799, HPA076570	Approved		Uncertain	Vesicles<br>Cytosol		Tissue enhanced	Tissue enriched	6	adrenal gland: 9.5	testis: 1.6	Cell line enhanced		HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1
NTSR2	NTR2	ENSG00000169006	Neurotensin receptor 2	2	11658178-11670164	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	25	cerebral cortex: 25.0	ovary: 0.9	Not detected		
ODC1	ODC	ENSG00000115758	Ornithine decarboxylase 1	2	10439968-10448504	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001536, CAB035996	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:3.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 242.0	Expressed in all		
OPRD1		ENSG00000116329	Opioid receptor delta 1	1	28812142-28871267	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA070831	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.6	adrenal gland: 0.8	Group enriched	12	RH-30: 15.8;SCLC-21H: 7.6;SH-SY5Y: 6.9;WM-115: 21.7
OPRK1	KOR, OPRK	ENSG00000082556	Opioid receptor kappa 1	8	53225716-53251697	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022595, HPA067549	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 3.6;prostate: 2.8;testis: 1.3	placenta,skeletal muscle: 0.3	Group enriched	7	AF22: 4.5;U-937: 17.3
OPRM1	MOR1	ENSG00000112038	Opioid receptor mu 1	6	154010496-154246867	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014509, HPA067435	Enhanced	Supported				Not detected	Tissue enhanced		testis: 4.1	adrenal gland,esophagus: 1.2	Cell line enriched	29	SH-SY5Y: 7.7
OXTR		ENSG00000180914	Oxytocin receptor	3	8750408-8769628	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	13	breast: 65.4	fallopian tube: 4.9	Cell line enhanced		BJ: 357.1;BJ hTERT+: 104.6;BJ hTERT+ SV40 Large T+: 111.8;fHDF/TERT166: 330.6
P2RX4	P2X4	ENSG00000135124	Purinergic receptor P2X 4	12	121209857-121234106	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039494	Enhanced		Approved	Actin filaments<br>Cytosol	Endometrial cancer:6.30e-10 (favourable)	Expressed in all	Mixed			placenta: 33.8	Mixed		
P2RY12	HORK3, P2Y12, SP1999	ENSG00000169313	Purinergic receptor P2Y12	3	151337380-151384812	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013796, HPA014518	Enhanced					Tissue enriched	Tissue enriched	6	cerebral cortex: 83.8	lymph node: 13.1	Not detected		
P2RY2	P2U	ENSG00000175591	Purinergic receptor P2Y2	11	73218298-73236352	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022642	Uncertain		Uncertain	Cytosol	Pancreatic cancer:2.19e-5 (unfavourable)	Mixed	Tissue enhanced		esophagus: 18.9	skeletal muscle: 14.9	Cell line enhanced		HaCaT: 31.0;HL-60: 27.2;THP-1: 53.1
PAH	PH	ENSG00000171759	Phenylalanine hydroxylase	12	102836885-102958410	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028407, HPA031642	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:4.30e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 504.6;liver: 722.4	gallbladder: 125.9	Cell line enriched	26	Hep G2: 161.3
PARP1	ADPRT, PARP, PPOL	ENSG00000143799	Poly(ADP-ribose) polymerase 1	1	226360691-226408079	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727	Supported	Supported	Enhanced	Nucleus	Renal cancer:1.35e-5 (unfavourable), Liver cancer:3.40e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 198.4	Expressed in all		
PARP2	ADPRTL2	ENSG00000129484	Poly(ADP-ribose) polymerase 2	14	20343582-20357905	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052003	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:6.48e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 46.3	Expressed in all		
PARP3	ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3	ENSG00000041880	Poly(ADP-ribose) polymerase family member 3	3	51942345-51948867	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA067657	Supported				Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 53.0	Expressed in all		
PCSK9	FH3, HCHOLA3, NARC-1	ENSG00000169174	Proprotein convertase subtilisin/kexin type 9	1	55039548-55064852	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:2.40e-4 (unfavourable)	Mixed	Tissue enhanced		liver: 6.1;lung: 11.1	colon: 3.4	Cell line enhanced		A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4
PDCD1	CD279, hSLE1, PD-1, PD1, SLEB2	ENSG00000188389	Programmed cell death 1	2	241849881-241858908	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035981, CAB038418, CAB076386	Enhanced				Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable)	Mixed	Tissue enhanced		lymph node: 12.0	appendix: 3.3	Group enriched	13	MOLT-4: 4.6;RPMI-8226: 4.0
PDE10A		ENSG00000112541	Phosphodiesterase 10A	6	165327287-165986603	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB045998, HPA047200	Supported				Renal cancer:4.44e-7 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 14.5	testis: 12.2	Cell line enhanced		LHCN-M2: 14.4;SH-SY5Y: 11.1;TIME: 14.8
PDE3A	CGI-PDE	ENSG00000172572	Phosphodiesterase 3A	12	20369245-20684381	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014492	Uncertain		Supported	Cytosol	Renal cancer:1.72e-6 (unfavourable)	Expressed in all	Mixed			heart muscle: 35.4	Group enriched	8	AF22: 15.4;HEL: 26.9;HeLa: 53.3;HUVEC TERT2: 11.9;SH-SY5Y: 31.0;U-138 MG: 22.1
PDE4A	DPDE2	ENSG00000065989	Phosphodiesterase 4A	19	10416773-10469631	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017632, HPA043310, HPA076091	Uncertain		Supported	Plasma membrane		Expressed in all	Mixed			parathyroid gland: 34.0	Cell line enhanced		HMC-1: 32.2
PDE4B	DPDE4	ENSG00000184588	Phosphodiesterase 4B	1	65792514-66374579	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003005	Uncertain		Approved	Golgi apparatus<br>Cytosol	Renal cancer:5.04e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 67.0	Cell line enhanced		AN3-CA: 57.3;HUVEC TERT2: 77.6;NTERA-2: 56.0
PDE4C	DPDE1	ENSG00000105650	Phosphodiesterase 4C	19	18207961-18255419	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048975	Enhanced					Mixed	Mixed			endometrium: 7.4	Cell line enhanced		BEWO: 3.8;U-87 MG: 5.5
PDE4D	DPDE3	ENSG00000113448	Phosphodiesterase 4D	5	58969038-60522120	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045895	Approved		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol	Renal cancer:4.00e-5 (favourable)	Mixed	Mixed			bone marrow: 47.7	Cell line enhanced		A549: 56.1;AN3-CA: 65.2;HeLa: 68.4
PDE5A		ENSG00000138735	Phosphodiesterase 5A	4	119494395-119628991	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004729, HPA012873	Approved		Approved	Cytosol	Urothelial cancer:1.17e-4 (unfavourable), Cervical cancer:5.20e-4 (favourable)	Expressed in all	Mixed			prostate: 97.7	Cell line enhanced		BJ hTERT+: 38.5;HHSteC: 55.3
PDE7A	HCP1	ENSG00000205268	Phosphodiesterase 7A	8	65717510-65842322	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018770, HPA027340	Approved				Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 68.9	Expressed in all		
PDE7B		ENSG00000171408	Phosphodiesterase 7B	6	135851696-136195574	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023967	Uncertain		Approved	Nucleoplasm	Renal cancer:1.59e-4 (favourable)	Mixed	Mixed			ovary: 16.2	Cell line enhanced		EFO-21: 15.3;HSkMC: 16.3;U-2197: 10.6
PDGFRA	CD140a, GAS9, PDGFR2	ENSG00000134853	Platelet derived growth factor receptor alpha	4	54229097-54298247	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA004947, CAB018143	Supported		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 222.6	Cell line enhanced		ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDGFRB	CD140b, JTK12, PDGFR, PDGFR1	ENSG00000113721	Platelet derived growth factor receptor beta	5	150113837-150155872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB003842, CAB018144, HPA028499	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 193.8	Cell line enhanced		ASC diff: 923.6;ASC TERT1: 324.4
PDXK	C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79	ENSG00000160209	Pyridoxal kinase	21	43719094-43762307	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030196, HPA030197, HPA030198, CAB033918	Approved		Enhanced	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 47.5	Expressed in all		
PGF	D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760	ENSG00000119630	Placental growth factor	14	74941834-74955784	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA041624			Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 71.1;thyroid gland: 64.5	cervix, uterine: 30.1	Group enriched	6	BEWO: 398.0;HUVEC TERT2: 164.7
PGR	NR3C3, PR	ENSG00000082175	Progesterone receptor	11	101029624-101130524	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000068, HPA004751, HPA008428, HPA017176, CAB055100	Enhanced				Endometrial cancer:5.76e-8 (favourable)	Group enriched	Group enriched	6	cervix, uterine: 96.2;endometrium: 172.3;fallopian tube: 53.3;smooth muscle: 114.9	ovary: 19.5	Cell line enriched	349	T-47d: 157.7
PLA2G1B	PLA2, PLA2A, PPLA2	ENSG00000170890	Phospholipase A2 group IB	12	120322111-120327789	Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB022329, HPA047822, HPA060803	Enhanced		Enhanced	Cytosol		Tissue enriched	Tissue enriched	246	pancreas: 23843.3	ovary: 96.9	Cell line enhanced		Hep G2: 1.7;U-2 OS: 1.8
PLA2G2A	PLA2B, PLA2L	ENSG00000188257	Phospholipase A2 group IIA	1	19975431-19980416	Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA015236	Enhanced		Uncertain	Nucleus<br>Nucleoli	Melanoma:1.49e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 108.4;rectum: 177.5;small intestine: 233.7	duodenum: 85.7	Group enriched	11	Hep G2: 50.2;RT4: 53.3
PLA2G4A	cPLA2-alpha, PLA2G4	ENSG00000116711	Phospholipase A2 group IVA	1	186828953-186988981	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010050, HPA050062, HPA054206	Approved		Supported	Cytosol	Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 200.5	seminal vesicle: 68.3	Cell line enhanced		RPMI-8226: 50.7;U-2197: 61.7
PLA2G6	iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9	ENSG00000184381	Phospholipase A2 group VI	22	38111495-38205690	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA001171	Approved		Approved	Microtubule organizing center<br>Cytosol	Urothelial cancer:1.55e-4 (favourable), Cervical cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			testis: 60.2	Cell line enhanced		HEL: 55.1
PLAT		ENSG00000104368	Plasminogen activator, tissue type	8	42175233-42207724	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003412, CAB009335	Supported		Approved	Actin filaments	Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable)	Expressed in all	Tissue enriched	5	parathyroid gland: 709.4	urinary bladder: 135.9	Cell line enhanced		CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6
PLAU	UPA, URK	ENSG00000122861	Plasminogen activator, urokinase	10	73909177-73917497	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008719	Approved				Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 60.3	Cell line enhanced		CAPAN-2: 757.8;LHCN-M2: 690.9;RPTEC TERT1: 2356.8;U-251 MG: 715.9
PLAUR	CD87, UPAR, URKR	ENSG00000011422	Plasminogen activator, urokinase receptor	19	43646095-43670547	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050843, CAB073533	Uncertain		Supported	Plasma membrane	Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 428.5	Cell line enhanced		U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6
PLCL1	PLC-L, PLCE, PLCL, PPP1R127, PRIP	ENSG00000115896	Phospholipase C like 1	2	197804702-198572581	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031849	Enhanced				Renal cancer:3.91e-7 (favourable)	Mixed	Mixed			kidney: 34.3	Cell line enhanced		HUVEC TERT2: 7.3;K-562: 13.7;Karpas-707: 7.9;MOLT-4: 8.6
PLG		ENSG00000122194	Plasminogen	6	160702238-160753315	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000668, CAB016678, HPA021602, HPA048823, HPA053770	Supported		Uncertain	Vesicles	Renal cancer:4.22e-4 (favourable)	Tissue enriched	Tissue enriched	6	liver: 1749.3	kidney: 313.4	Cell line enhanced		RH-30: 1.0
PLIN3	M6PRBP1, PP17, TIP47	ENSG00000105355	Perilipin 3	19	4838341-4867768	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006427, HPA066538	Uncertain		Enhanced	Lipid droplets<br>Cytosol	Renal cancer:9.15e-7 (unfavourable), Lung cancer:7.67e-6 (unfavourable), Liver cancer:3.27e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 115.7	Expressed in all		
PNLIP	PL	ENSG00000175535	Pancreatic lipase	10	116545931-116567855	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062430, HPA062494	Enhanced					Tissue enriched	Tissue enriched	325	pancreas: 93703.0	ovary: 288.0	Cell line enhanced		U-2 OS: 1.3
PNP	NP, PUNP	ENSG00000198805	Purine nucleoside phosphorylase	14	20468954-20477094	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001625	Enhanced		Supported	Cytosol	Renal cancer:2.24e-4 (favourable), Liver cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 698.2	Expressed in all		
POLA1	NSX, p180, POLA	ENSG00000101868	DNA polymerase alpha 1, catalytic subunit	X	24693919-24996986	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002947, CAB012274	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.80e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 8.7	Expressed in all		
POLB		ENSG00000070501	DNA polymerase beta	8	42338454-42371808	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011616, HPA049104	Enhanced		Approved	Vesicles	Renal cancer:2.15e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Urothelial cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.7	Expressed in all		
POLE	POLE1	ENSG00000177084	DNA polymerase epsilon, catalytic subunit	12	132623753-132687365	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058210, HPA067385			Enhanced	Nucleus<br>Plasma membrane	Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
POLE2	DPE2	ENSG00000100479	DNA polymerase epsilon 2, accessory subunit	14	49643555-49688422	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027555	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Mixed			bone marrow: 10.7	Mixed		
POLE3	CHARAC17, CHRAC17, p17, Ybl1	ENSG00000148229	DNA polymerase epsilon 3, accessory subunit	9	113407235-113410672	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047945	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:8.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.4	Expressed in all		
POLE4	p12	ENSG00000115350	DNA polymerase epsilon 4, accessory subunit	2	74958492-74970128	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054979, HPA071815	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 12.8	Mixed		
PPARA	hPPAR, NR1C1, PPAR	ENSG00000186951	Peroxisome proliferator activated receptor alpha	22	46150521-46243756	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058901, HPA067049, CAB075701	Supported		Enhanced	Nucleus	Renal cancer:4.39e-9 (favourable)	Expressed in all	Expressed in all			kidney: 24.2	Mixed		
PPARD	FAAR, NR1C2, NUC1, NUCII	ENSG00000112033	Peroxisome proliferator activated receptor delta	6	35342558-35428191	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017635	Approved				Liver cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 40.2	Expressed in all		
PPARG	NR1C3, PPARG1, PPARG2, PPARgamma	ENSG00000132170	Peroxisome proliferator activated receptor gamma	3	12287368-12434356	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004282, HPA051239, HPA063663	Approved		Enhanced	Nucleus<br>Vesicles	Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 173.3	placenta: 59.2	Cell line enhanced		ASC diff: 131.6;BEWO: 223.4;RT4: 116.1
PPP3R2	PPP3RL	ENSG00000188386	Protein phosphatase 3 regulatory subunit B, beta	9	101591615-101595021	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047157	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enriched	1372	testis: 137.1	all non-specific tissues: 0.0	Not detected		
PRDX5	ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10	ENSG00000126432	Peroxiredoxin 5	11	64318088-64321811	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008661, HPA037915, HPA037916	Enhanced		Enhanced	Mitochondria<br>Cytosol	Renal cancer:1.24e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 606.1	Expressed in all		
PRKAA1	AMPKa1	ENSG00000132356	Protein kinase AMP-activated catalytic subunit alpha 1	5	40759379-40798374	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005050, HPA035409, HPA064946	Supported		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 74.4	Expressed in all		
PRKAB1		ENSG00000111725	Protein kinase AMP-activated non-catalytic subunit beta 1	12	119667753-119681630	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004247, CAB005058	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.40e-9 (favourable), Endometrial cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			kidney: 53.5	Expressed in all		
PRLR		ENSG00000113494	Prolactin receptor	5	35048756-35230589	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		placenta: 70.9	kidney: 33.1	Cell line enriched	22	T-47d: 356.8
PROC		ENSG00000115718	Protein C, inactivator of coagulation factors Va and VIIIa	2	127418427-127429246	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005550, CAB016721, CAB016792	Supported					Tissue enriched	Tissue enriched	12	liver: 140.4	kidney: 12.0	Cell line enriched	12	Hep G2: 105.5
PROS1	PROS	ENSG00000184500	Protein S (alpha)	3	93873033-93974066	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007724, HPA023974	Enhanced				Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 177.6	heart muscle: 78.3	Cell line enhanced		ASC diff: 98.8;SK-MEL-30: 127.4
PSMB1	HC5, PMSB1	ENSG00000008018	Proteasome subunit beta 1	6	170535117-170553341	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029635, HPA029637, CAB033911	Enhanced		Supported	Nucleus	Renal cancer:3.76e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 320.2	Expressed in all		
PSMB10	beta2i, LMP10, MECL1, MGC1665	ENSG00000205220	Proteasome subunit beta 10	16	67934502-67937087	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030224, HPA030225, CAB034384	Enhanced		Enhanced	Cytosol	Urothelial cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 91.2	Mixed		
PSMB2	HC7-I	ENSG00000126067	Proteasome subunit beta 2	1	35599544-35641844	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026322, HPA026324	Approved		Enhanced	Nucleoplasm	Liver cancer:3.49e-7 (unfavourable), Renal cancer:2.80e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 43.3	Expressed in all		
PSMB5	MB1, X	ENSG00000100804	Proteasome subunit beta 5	14	23016543-23035230	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049518, HPA061796	Approved		Supported	Nucleus<br>Centrosome	Liver cancer:2.90e-5 (unfavourable), Ovarian cancer:1.08e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable), Urothelial cancer:4.73e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 141.7	Expressed in all		
PSMB8	beta5i, D6S216E, LMP7, PSMB5i, RING10	ENSG00000204264	Proteasome subunit beta 8	6	32840717-32844703	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046995, HPA050327	Enhanced		Approved	Vesicles<br>Cytokinetic bridge	Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable)	Expressed in all	Mixed			lymph node: 23.0	Mixed		
PSMB9	beta1i, LMP2, PSMB6i, RING12	ENSG00000240065	Proteasome subunit beta 9	6	32844136-32859585	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015180, HPA042818, HPA053280	Enhanced		Supported	Cytosol	Renal cancer:1.33e-4 (unfavourable)	Expressed in all	Mixed			spleen: 39.1	Cell line enhanced		Daudi: 46.2;REH: 43.8
PTGER1	EP1	ENSG00000160951	Prostaglandin E receptor 1	19	14472466-14475362	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enhanced		kidney: 2.9;spleen: 2.5	lung: 0.7	Cell line enhanced		HEL: 2.2;PC-3: 2.9;SH-SY5Y: 1.9
PTGER2	EP2	ENSG00000125384	Prostaglandin E receptor 2	14	52314305-52328606	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level						Renal cancer:4.16e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 27.3	Cell line enhanced		ASC TERT1: 50.0;HHSteC: 38.3;HSkMC: 41.8
PTGER3	EP3	ENSG00000050628	Prostaglandin E receptor 3	1	70852353-71047808	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA010689	Uncertain				Renal cancer:3.50e-4 (unfavourable)	Group enriched	Group enriched	7	adipose tissue: 58.6;endometrium: 115.3;kidney: 88.3;smooth muscle: 105.2	skin: 13.9	Group enriched	5	ASC diff: 19.6;HAP1: 21.6;HDLM-2: 30.4;HEL: 14.0;T-47d: 68.0
PTGER4	EP4	ENSG00000171522	Prostaglandin E receptor 4	5	40679498-40693735	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA011226, HPA012756	Approved				Urothelial cancer:2.48e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 48.1	Cell line enhanced		HDLM-2: 33.9;RT4: 28.7;TIME: 37.0
PTGFR	FP	ENSG00000122420	Prostaglandin F receptor	1	78303884-78539749	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		endometrium: 30.5;smooth muscle: 25.7	urinary bladder: 12.9	Group enriched	7	ASC TERT1: 193.6;HSkMC: 63.3
PTGIR	IP	ENSG00000160013	Prostaglandin I2 (prostacyclin) receptor (IP)	19	46620468-46625118	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 13.9	appendix: 8.2	Cell line enhanced		BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3
PTGIS	CYP8A1, PGIS	ENSG00000124212	Prostaglandin I2 synthase	20	49503874-49568146	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009517, HPA014193, HPA052244	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:4.74e-8 (unfavourable), Urothelial cancer:9.99e-5 (unfavourable)	Expressed in all	Mixed			fallopian tube: 78.2	Cell line enhanced		ASC diff: 30.9;ASC TERT1: 31.6;U-2197: 133.1
PTGS1	COX1, PGHS-1, PTGHS	ENSG00000095303	Prostaglandin-endoperoxide synthase 1	9	122370530-122395703	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002834, CAB020315	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 161.6	fallopian tube: 86.1	Cell line enhanced		ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6
PTGS2	COX2	ENSG00000073756	Prostaglandin-endoperoxide synthase 2	1	186671791-186680427	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB000113, HPA001335	Approved		Supported	Endoplasmic reticulum	Renal cancer:9.79e-4 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 180.6	cervix, uterine: 99.3	Group enriched	7	BJ: 78.6;BJ hTERT+: 327.8
PTH2R	PTHR2	ENSG00000144407	Parathyroid hormone 2 receptor	2	208359714-208854503	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA010655	Approved					Tissue enhanced	Mixed			bone marrow: 2.9	Group enriched	9	EFO-21: 10.1;HEL: 14.3;HL-60: 3.1;SH-SY5Y: 6.7
QPRT	QPRTase	ENSG00000103485	Quinolinate phosphoribosyltransferase	16	29679008-29698699	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011887	Approved				Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 112.3	Cell line enhanced		EFO-21: 469.3
RAF1	c-Raf, CRAF, Raf-1	ENSG00000132155	Raf-1 proto-oncogene, serine/threonine kinase	3	12583601-12664226	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002640, CAB019291	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 100.7	Expressed in all		
RAMP1		ENSG00000132329	Receptor activity modifying protein 1	2	237858893-237912114	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA057814			Supported	Nucleoplasm<br>Nuclear membrane	Stomach cancer:1.68e-4 (unfavourable), Liver cancer:7.61e-4 (favourable)	Expressed in all	Tissue enhanced		endometrium: 234.1	smooth muscle: 171.5	Cell line enhanced		HDLM-2: 126.9;PC-3: 142.8;SH-SY5Y: 202.6
RAMP2		ENSG00000131477	Receptor activity modifying protein 2	17	42758447-42763041	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052020			Approved	Vesicles		Expressed in all	Mixed			lung: 178.6	Cell line enhanced		ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7
RAMP3		ENSG00000122679	Receptor activity modifying protein 3	7	45157791-45186302	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Liver cancer:2.50e-6 (favourable), Cervical cancer:2.89e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 120.2	thyroid gland: 66.3	Cell line enhanced		Karpas-707: 1.8
RARA	NR1B1, RAR	ENSG00000131759	Retinoic acid receptor alpha	17	40309192-40357643	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058282			Supported	Nucleus<br>Cytosol	Endometrial cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 68.6	Expressed in all		
RARB	HAP, NR1B2, RRB2	ENSG00000077092	Retinoic acid receptor beta	3	25174332-25597932	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002617, HPA004174	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.43e-5 (favourable)	Expressed in all	Mixed			placenta: 20.6	Cell line enhanced		HEK93: 14.7;HUVEC TERT2: 11.2;WM-115: 36.1
RARG	NR1B3, RARC	ENSG00000172819	Retinoic acid receptor gamma	12	53210567-53232980	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053883	Supported		Supported	Nucleoplasm	Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable)	Expressed in all	Tissue enhanced		skin: 143.4	esophagus: 77.3	Mixed		
REN		ENSG00000143839	Renin	1	204154819-204190324	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005131, CAB025903	Approved				Renal cancer:6.45e-5 (unfavourable)	Tissue enriched	Tissue enhanced		kidney: 51.2;placenta: 21.0	endometrium: 8.9	Cell line enhanced		BJ: 1.7;HMC-1: 2.3;SK-BR-3: 1.4
RET	CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51	ENSG00000165731	Ret proto-oncogene	10	43077027-43130351	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002581, HPA008356, HPA008495, CAB018342	Approved	Supported	Supported	Vesicles<br>Plasma membrane<br>Cytosol	Endometrial cancer:5.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	parathyroid gland: 154.5	adrenal gland: 29.8	Cell line enriched	5	SH-SY5Y: 404.3
RFK	FLJ11149, RIFK	ENSG00000135002	Riboflavin kinase	9	76385517-76394517	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023259, CAB033887, HPA057163	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			cerebral cortex: 37.8	Expressed in all		
RPL3	L3	ENSG00000100316	Ribosomal protein L3	22	39312882-39320389	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA003365, HPA055361	Uncertain		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			ovary: 5675.2	Expressed in all		
RRM1		ENSG00000167325	Ribonucleotide reductase catalytic subunit M1	11	4094707-4138876	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022093, HPA057265, HPA064297	Enhanced		Enhanced	Cytosol	Liver cancer:1.53e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 60.4	Expressed in all		
RRM2		ENSG00000171848	Ribonucleotide reductase regulatory subunit M2	2	10122328-10131419	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056994	Enhanced		Supported	Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 47.5	Mixed		
RRM2B	p53R2	ENSG00000048392	Ribonucleotide reductase regulatory TP53 inducible subunit M2B	8	102204502-102239118	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006854, HPA028812	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 75.1	Expressed in all		
RXRA	NR2B1	ENSG00000186350	Retinoid X receptor alpha	9	134317098-134440585	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004565, CAB005352	Supported		Supported	Nucleus<br>Golgi apparatus	Renal cancer:5.58e-4 (unfavourable), Pancreatic cancer:7.02e-4 (favourable)	Expressed in all	Mixed			esophagus: 25.8	Mixed		
RXRB	H-2RIIBP, NR2B2, RCoR-1	ENSG00000204231	Retinoid X receptor beta	6	33193588-33200688	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002003, HPA063653	Supported		Supported	Nucleus		Expressed in all	Mixed			epididymis: 15.7	Cell line enhanced		RH-30: 8.5;T-47d: 8.2
RXRG	NR2B3	ENSG00000143171	Retinoid X receptor gamma	1	165400917-165445355	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002615, HPA012933	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Thyroid cancer:9.40e-5 (favourable)	Group enriched	Tissue enhanced		skeletal muscle: 16.7	cervix, uterine: 4.7	Cell line enriched	6	SK-MEL-30: 29.1
RYR1	CCO, MHS, MHS1, PPP1R137, RYR	ENSG00000196218	Ryanodine receptor 1	19	38433699-38587564	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056416	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Cytosol		Mixed	Tissue enriched	31	skeletal muscle: 572.4	esophagus: 18.6	Cell line enhanced		HaCaT: 16.8;RH-30: 14.8;SiHa: 32.7;U-2 OS: 13.2
RYR2	ARVC2, ARVD2, VTSIP	ENSG00000198626	Ryanodine receptor 2	1	237042205-237833988	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020028	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	8	heart muscle: 65.9	cerebral cortex: 7.9	Cell line enhanced		HDLM-2: 4.8;HEK93: 6.3;K-562: 2.0;NTERA-2: 2.5;U-937: 2.5
S1PR1	CD363, D1S3362, edg-1, EDG1	ENSG00000170989	Sphingosine-1-phosphate receptor 1	1	101236888-101241518	Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010104, HPA075568	Supported		Supported	Vesicles	Urothelial cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 86.8	Cell line enhanced		BJ: 53.9;HUVEC TERT2: 149.1;TIME: 81.9;U-251 MG: 103.4
S1PR5	Edg-8, EDG8	ENSG00000180739	Sphingosine-1-phosphate receptor 5	19	10512742-10517931	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029683	Enhanced				Renal cancer:6.71e-7 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 14.9;skin: 22.1	spleen: 12.0	Cell line enhanced		HaCaT: 25.0;RT4: 14.8;T-47d: 10.9;U-2 OS: 10.7
SCN10A	hPN3, Nav1.8, PN3, SNS	ENSG00000185313	Sodium voltage-gated channel alpha subunit 10	3	38696802-38794010	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Not detected			testis: 0.3	Not detected		
SCN11A	NaN, Nav1.9, SCN12A, SNS-2	ENSG00000168356	Sodium voltage-gated channel alpha subunit 11	3	38845769-38950561	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA036746, HPA036747	Uncertain					Not detected	Tissue enhanced		placenta: 3.7;spleen: 5.3	testis: 2.0	Cell line enhanced		HDLM-2: 1.1
SCN1A	FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI	ENSG00000144285	Sodium voltage-gated channel alpha subunit 1	2	165989160-166149214	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA078664			Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Tissue enriched	Group enriched	41	cerebral cortex: 10.3;fallopian tube: 2.9;lung: 2.2	adrenal gland,placenta,testis: 0.1	Cell line enhanced		AF22: 1.1;ASC TERT1: 4.4;Hep G2: 1.1
SCN1B		ENSG00000105711	Sodium voltage-gated channel beta subunit 1	19	35030466-35040449	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.38e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 145.1	cerebral cortex: 52.4	Cell line enhanced		A549: 15.7;TIME: 21.3
SCN2A	HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2	ENSG00000136531	Sodium voltage-gated channel alpha subunit 2	2	165194993-165392310	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB022567	Enhanced					Tissue enhanced	Tissue enriched	26	cerebral cortex: 56.6	kidney: 2.1	Cell line enhanced		U-138 MG: 3.6;U-266/84: 5.7;U-87 MG: 2.2
SCN2B		ENSG00000149575	Sodium voltage-gated channel beta subunit 2	11	118161951-118176673	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Group enriched	9	cerebral cortex: 34.7;heart muscle: 7.1	smooth muscle: 2.4	Cell line enhanced		U-2197: 1.6
SCN3A	Nav1.3	ENSG00000153253	Sodium voltage-gated channel alpha subunit 3	2	165087522-165204067	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA035396	Approved					Tissue enriched	Tissue enriched	7	cerebral cortex: 13.6	adrenal gland: 1.9	Cell line enhanced		Karpas-707: 7.8;MOLT-4: 26.0;RPTEC TERT1: 11.6;SH-SY5Y: 7.3
SCN3B	HSA243396	ENSG00000166257	Sodium voltage-gated channel beta subunit 3	11	123629187-123655244	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041707			Approved	Intermediate filaments<br>Cytosol		Tissue enhanced	Tissue enriched	11	cerebral cortex: 132.1	adrenal gland: 11.5	Cell line enhanced		hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0
SCN4A	HYKPP, HYPP, Nav1.4, SkM1	ENSG00000007314	Sodium voltage-gated channel alpha subunit 4	17	63938554-63972918	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA053992			Approved	Nucleoplasm<br>Microtubule organizing center		Tissue enhanced	Group enriched	9	adipose tissue: 12.4;skeletal muscle: 47.2	thyroid gland: 3.3	Group enriched	13	REH: 13.6;RH-30: 43.5
SCN4B	LQT10	ENSG00000177098	Sodium voltage-gated channel beta subunit 4	11	118133377-118152888	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017293	Approved					Mixed	Tissue enhanced		adipose tissue: 25.0	thyroid gland: 17.0	Cell line enhanced		AN3-CA: 1.2;NTERA-2: 1.4;U-2 OS: 1.4
SCN5A	CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1	ENSG00000183873	Sodium voltage-gated channel alpha subunit 5	3	38548057-38649673	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	18	heart muscle: 27.8	cervix, uterine: 1.5	Cell line enhanced		LHCN-M2: 23.1;RH-30: 22.0
SCN9A	ETHA, Nav1.7, NE-NA, NENA, PN1	ENSG00000169432	Sodium voltage-gated channel alpha subunit 9	2	166195185-166375993	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB013679, HPA061843	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Renal cancer:2.30e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 9.1	placenta: 5.9	Cell line enhanced		BJ: 20.5;BJ hTERT+: 13.6;HHSteC: 13.7
SCNN1A	ENaCalpha, SCNN1	ENSG00000111319	Sodium channel epithelial 1 alpha subunit	12	6346843-6377730	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012743	Enhanced				Renal cancer:9.21e-8 (favourable), Pancreatic cancer:2.30e-4 (unfavourable), Ovarian cancer:8.86e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 95.1	Cell line enhanced		CAPAN-2: 264.6;HBEC3-KT: 145.5;RPTEC TERT1: 78.8;RT4: 91.1;SK-BR-3: 72.7
SCNN1B	ENaCbeta	ENSG00000168447	Sodium channel epithelial 1 beta subunit	16	23278231-23381299	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015612	Uncertain				Renal cancer:2.09e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 72.0	esophagus: 44.8	Cell line enhanced		hTCEpi: 24.0;RT4: 14.6;U-266/70: 41.7;U-266/84: 14.3
SCNN1D	dNaCh, ENaCdelta	ENSG00000162572	Sodium channel epithelial 1 delta subunit	1	1280436-1292029	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026884	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable)	Mixed	Tissue enhanced		testis: 13.8	cerebral cortex: 7.3	Mixed		
SCNN1G	ENaCgamma, SCNEG	ENSG00000166828	Sodium channel epithelial 1 gamma subunit	16	23182715-23216883	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071194			Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:3.20e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 24.6;kidney: 46.7	thyroid gland: 9.5	Group enriched	5	hTCEpi: 33.4;RT4: 17.1
SCTR		ENSG00000080293	Secretin receptor	2	119439843-119525301	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA007269	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 26.7;lung: 12.7;pancreas: 14.4	stomach: 4.1	Cell line enhanced		Karpas-707: 2.2
SDHD	cybS, PGL, PGL1	ENSG00000204370	Succinate dehydrogenase complex subunit D	11	112086773-112120013	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045727	Approved				Renal cancer:1.99e-10 (favourable)	Expressed in all	Expressed in all			kidney: 305.5	Expressed in all		
SDHD	cybS, PGL, PGL1	ENSG00000255292	Succinate dehydrogenase complex subunit D	11	112086824-112193805	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA045727	Uncertain					Not detected	Tissue enriched	13	colon: 7.8	parathyroid gland: 0.5	Cell line enhanced		A549: 23.8;CACO-2: 57.0;Hep G2: 19.6;hTEC/SVTERT24-B: 20.1;RT4: 30.5
SERPINB2	HsT1201, PAI2, PLANH2	ENSG00000197632	Serpin family B member 2	18	63871692-63903890	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015480	Supported				Urothelial cancer:1.55e-5 (unfavourable)	Tissue enhanced	Group enriched	6	esophagus: 260.7;placenta: 70.3;skin: 105.8;tonsil: 72.9	bone marrow: 22.2	Group enriched	6	HaCaT: 611.4;U-138 MG: 792.9;U-2197: 1151.1
SERPINC1	AT3, ATIII, MGC22579	ENSG00000117601	Serpin family C member 1	1	173903804-173917378	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001816, CAB016790, HPA024007	Supported				Liver cancer:3.40e-5 (favourable)	Tissue enriched	Tissue enriched	670	liver: 2517.8	kidney: 3.7	Cell line enriched	26	Hep G2: 55.1
SERPIND1	D22S673, HC-II, HC2, HCF2, HLS2	ENSG00000099937	Serpin family D member 1	22	20773879-20787720	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB008639, HPA055767	Supported		Approved	Vesicles	Endometrial cancer:4.09e-4 (favourable)	Tissue enriched	Tissue enriched	16	liver: 585.3	parathyroid gland: 36.2	Cell line enriched	8	Hep G2: 126.1
SERPINE1	PAI, PAI1, PLANH1	ENSG00000106366	Serpin family E member 1	7	101127089-101139266	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA050039, CAB068501	Uncertain		Approved	Cytosol	Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 580.3;placenta: 600.2	adipose tissue: 215.8	Cell line enhanced		TIME: 8072.1;U-138 MG: 4492.2;U-251 MG: 3465.4
SHMT1	CSHMT, MGC15229, MGC24556, SHMT	ENSG00000176974	Serine hydroxymethyltransferase 1	17	18327860-18363563	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023314	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:8.54e-6 (favourable), Liver cancer:2.52e-4 (favourable)	Expressed in all	Expressed in all			kidney: 271.5	Expressed in all		
SI		ENSG00000090402	Sucrase-isomaltase	3	164978898-165078495	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011897	Enhanced					Tissue enhanced	Group enriched	15	duodenum: 547.3;small intestine: 493.2	rectum: 34.5	Cell line enhanced		BEWO: 1.0;CACO-2: 1.3;RPMI-8226: 1.3;SH-SY5Y: 1.2
SIGMAR1	OPRS1, SR-BP1	ENSG00000147955	Sigma non-opioid intracellular receptor 1	9	34634722-34637809	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013470, HPA018002, HPA024071	Approved				Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 67.8	Expressed in all		
SIRT5		ENSG00000124523	Sirtuin 5	6	13574529-13615158	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021798, HPA022002, HPA022992	Approved		Enhanced	Mitochondria	Renal cancer:8.76e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.1	Expressed in all		
SLAMF7	19A, CD319, CRACC, CS1	ENSG00000026751	SLAM family member 7	1	160739057-160754821	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015445, HPA055945, HPA061654	Enhanced		Approved	Vesicles	Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)	Mixed	Mixed			spleen: 58.3	Group enriched	7	SK-MEL-30: 45.6;U-266/70: 216.2
SLC12A1	NKCC2	ENSG00000074803	Solute carrier family 12 member 1	15	48191664-48304078	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014967, HPA018107	Enhanced		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	477	kidney: 780.2	testis: 1.6	Cell line enriched	19	RPTEC TERT1: 19.2
SLC12A2	BSC, BSC2, NKCC1, PPP1R141	ENSG00000064651	Solute carrier family 12 member 2	5	128083766-128189688	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020130, HPA063697	Approved		Approved	Vesicles<br>Plasma membrane	Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable)	Expressed in all	Expressed in all			rectum: 65.4	Expressed in all		
SLC12A3	NCCT	ENSG00000070915	Solute carrier family 12 member 3	16	56865207-56915850	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028748	Enhanced					Tissue enhanced	Tissue enriched	109	kidney: 109.8	lymph node: 1.0	Group enriched	11	BEWO: 7.0;HAP1: 4.1;HeLa: 5.5
SLC12A4	KCC1	ENSG00000124067	Solute carrier family 12 member 4	16	67943474-67969601	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041138	Approved		Approved	Endosomes	Renal cancer:2.25e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.9	Mixed		
SLC12A5	KCC2, KIAA1176	ENSG00000124140	Solute carrier family 12 member 5	20	46021690-46060152	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072058	Enhanced				Glioma:8.45e-4 (unfavourable)	Mixed	Tissue enriched	8	cerebral cortex: 94.2	adrenal gland: 11.9	Cell line enhanced		NB-4: 32.3;U-2 OS: 29.1
SLC18A1	CGAT, VAT1, VMAT1	ENSG00000036565	Solute carrier family 18 member A1	8	20144855-20183206	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006877, HPA063797	Enhanced					Tissue enhanced	Tissue enriched	11	adrenal gland: 32.6	rectum: 3.0	Cell line enriched	9	SH-SY5Y: 70.0
SLC18A2	SVAT, SVMT, VMAT2	ENSG00000165646	Solute carrier family 18 member A2	10	117241093-117279430	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA073224	Approved					Mixed	Tissue enhanced		cervix, uterine: 47.6	adrenal gland: 19.0	Cell line enriched	18	HMC-1: 308.7
SLC22A11	OAT4	ENSG00000168065	Solute carrier family 22 member 11	11	64555626-64572875	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026076	Approved				Renal cancer:3.68e-5 (favourable)	Group enriched	Group enriched	114	epididymis: 10.0;kidney: 26.0;placenta: 44.8	seminal vesicle: 0.2	Cell line enhanced		BEWO: 1.2
SLC22A12	OAT4L, RST, URAT1	ENSG00000197891	Solute carrier family 22 member 12	11	64590641-64602353	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024575	Enhanced				Renal cancer:2.63e-4 (favourable)	Group enriched	Tissue enriched	198	kidney: 105.0	adipose tissue: 0.5	Not detected		
SLC22A6	OAT1, PAHT, ROAT1	ENSG00000197901	Solute carrier family 22 member 6	11	62936385-62984983	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074559, CAB075704	Enhanced					Tissue enriched	Tissue enriched	64	kidney: 200.2	cerebral cortex: 3.1	Not detected		
SLC22A8	OAT3	ENSG00000149452	Solute carrier family 22 member 8	11	62989154-63015839	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044174	Enhanced					Tissue enhanced	Tissue enriched	395	kidney: 339.8	cerebral cortex: 0.8	Not detected		
SLC25A4	ANT1, PEO2, PEO3, T1	ENSG00000151729	Solute carrier family 25 member 4	4	185143241-185150382	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Enhanced	Mitochondria	Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 122.1;skeletal muscle: 66.2	cerebral cortex: 38.1	Mixed		
SLC25A5	2F1, ANT2, T2, T3	ENSG00000005022	Solute carrier family 25 member 5	X	119468400-119471319	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Supported	Mitochondria	Renal cancer:8.06e-6 (favourable), Cervical cancer:7.35e-4 (favourable), Colorectal cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 769.6	Expressed in all		
SLC25A6	ANT3, ANT3Y, MGC17525	ENSG00000169100	Solute carrier family 25 member 6	X	1386152-1392724	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			ovary: 291.7	Expressed in all		
SLC52A2	D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2	ENSG00000185803	Solute carrier family 52 member 2	8	144354135-144361272	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063036	Approved				Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 20.8	Expressed in all		
SLC5A2	SGLT2	ENSG00000140675	Solute carrier family 5 member 2	16	31483002-31490860	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041603	Enhanced					Not detected	Tissue enriched	10	kidney: 26.5	testis: 2.7	Not detected		
SLC6A1	GABATHG, GABATR, GAT1	ENSG00000157103	Solute carrier family 6 member 1	3	10992724-11039247	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013341, CAB022293	Enhanced		Uncertain	Mitochondria	Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable)	Group enriched	Group enriched	5	cerebral cortex: 119.4;liver: 50.4	parathyroid gland: 16.0	Not detected		
SLC6A2	NAT1, NET, NET1, SLC6A5	ENSG00000103546	Solute carrier family 6 member 2	16	55655604-55706192	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004057, HPA076311, CAB078195	Enhanced	Supported	Approved	Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		adrenal gland: 29.2;placenta: 18.4;skin: 15.7	testis: 11.4	Cell line enriched	35	SH-SY5Y: 519.4
SLC6A3	DAT, DAT1	ENSG00000142319	Solute carrier family 6 member 3	5	1392790-1445430	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012763, HPA013602, CAB016249, CAB078172	Supported	Supported	Approved	Vesicles	Renal cancer:3.40e-7 (unfavourable)	Tissue enriched	Not detected			thyroid gland: 0.3	Not detected		
SLC6A4	5-HTT, HTT, OCD1, SERT1	ENSG00000108576	Solute carrier family 6 member 4	17	30194319-30236002	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071354, HPA074728		Supported	Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Group enriched	10	duodenum: 10.4;lung: 44.2;placenta: 26.4;small intestine: 45.3	esophagus: 3.1	Cell line enhanced		BEWO: 1.9;CACO-2: 3.2;Hep G2: 7.1
SLC6A8	CRTR, CT1	ENSG00000130821	Solute carrier family 6 member 8	X	153688099-153696593	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 89.2	Mixed		
SLC7A11	xCT	ENSG00000151012	Solute carrier family 7 member 11	4	138164097-138242349	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064215			Supported	Vesicles	Ovarian cancer:1.77e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.4	epididymis: 8.2	Expressed in all		
SLC8A1	NCX1	ENSG00000183023	Solute carrier family 8 member A1	2	40097270-40611053	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022694, HPA070007	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		heart muscle: 78.0	seminal vesicle: 37.6	Cell line enhanced		BJ: 24.4;fHDF/TERT166: 54.5
SLCO2B1	OATP-B, OATP2B1, SLC21A9	ENSG00000137491	Solute carrier organic anion transporter family member 2B1	11	75100563-75206549	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020659	Uncertain					Expressed in all	Expressed in all			liver: 123.1	Cell line enhanced		CACO-2: 75.7;HEL: 13.5;Hep G2: 14.2;HMC-1: 23.5
SMO	FZD11, SMOH	ENSG00000128602	Smoothened, frizzled class receptor	7	129188872-129213545	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011446	Approved					Expressed in all	Mixed			ovary: 30.4	Cell line enhanced		AN3-CA: 84.8;NTERA-2: 69.7
SMOX	C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO	ENSG00000088826	Spermine oxidase	20	4120980-4187747	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047117, HPA060198	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.7	gallbladder: 23.5	Cell line enhanced		A549: 104.6;Karpas-707: 139.7
SMS	MRSR, SPMSY, SpS, SRS	ENSG00000102172	Spermine synthase	X	21940573-21994835	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029849, HPA029852	Approved		Approved	Nuclear bodies<br>Cytosol	Liver cancer:7.79e-8 (unfavourable), Renal cancer:7.85e-5 (unfavourable), Head and neck cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 202.4	Expressed in all		
SNAP25	bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25	ENSG00000132639	Synaptosome associated protein 25	20	10218830-10307418	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000360, HPA001830	Enhanced	Supported				Group enriched	Tissue enriched	31	cerebral cortex: 1759.0	adrenal gland: 57.2	Cell line enhanced		SCLC-21H: 92.0;SH-SY5Y: 49.5;U-87 MG: 54.7
SOAT1	ACAT, SOAT, STAT	ENSG00000057252	Sterol O-acyltransferase 1	1	179293714-179358680	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB009533, HPA047171	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Tissue enhanced		adrenal gland: 218.2	prostate: 45.1	Expressed in all		
SQLE		ENSG00000104549	Squalene epoxidase	8	124998497-125022283	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018038, HPA020762	Enhanced		Uncertain	Vesicles<br>Cytosol	Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 107.8	Expressed in all		
SRC	ASV, c-src, SRC1	ENSG00000197122	SRC proto-oncogene, non-receptor tyrosine kinase	20	37344685-37406050	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004023, HPA030875	Approved		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 43.6	Mixed		
SRD5A1		ENSG00000145545	Steroid 5 alpha-reductase 1	5	6633343-6674386	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA051402	Approved				Endometrial cancer:8.73e-6 (unfavourable)	Expressed in all	Mixed			skin: 16.8	Mixed		
SRD5A2		ENSG00000277893	Steroid 5 alpha-reductase 2	2	31522480-31581067	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	11	epididymis: 27.9;fallopian tube: 31.6;liver: 30.6;prostate: 26.6;seminal vesicle: 24.5	testis: 2.5	Cell line enhanced		RT4: 1.2
SSTR1		ENSG00000139874	Somatostatin receptor 1	14	38207999-38213067	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA031506	Approved				Renal cancer:4.28e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 13.6;duodenum: 14.2;stomach: 21.4	small intestine: 9.1	Cell line enhanced		BJ: 102.5;BJ hTERT+: 27.1;fHDF/TERT166: 56.0
SSTR2		ENSG00000180616	Somatostatin receptor 2	17	73165012-73176633	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA007264	Uncertain		Supported	Cytosol	Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.9	spleen: 5.8	Cell line enriched	9	SCLC-21H: 14.9
SSTR5		ENSG00000162009	Somatostatin receptor 5	16	1078781-1080142	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA066503			Supported	Plasma membrane		Mixed	Tissue enhanced		adrenal gland: 1.2	kidney: 0.5	Group enriched	15	Hep G2: 10.4;PC-3: 50.7
SV2A	KIAA0736, SV2	ENSG00000159164	Synaptic vesicle glycoprotein 2A	1	149903318-149917882	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB002226, HPA007863	Enhanced		Approved	Cytosol	Renal cancer:3.22e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 166.9;parathyroid gland: 72.0	epididymis: 28.2	Cell line enhanced		NTERA-2: 65.6;SCLC-21H: 63.2
SYT2		ENSG00000143858	Synaptotagmin 2	1	202590596-202710417	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA030372, HPA063655	Enhanced	Supported	Approved	Vesicles		Tissue enriched	Tissue enhanced		adrenal gland: 1.8;cerebral cortex: 2.1	epididymis,testis: 1.0	Cell line enhanced		AF22: 8.4;NTERA-2: 5.8;U-2 OS: 1.8
TAAR1	TA1, TAR1, TRAR1	ENSG00000146399	Trace amine associated receptor 1	6	132644984-132646003	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055614	Approved					Tissue enhanced	Group enriched	17	fallopian tube: 2.2;stomach: 7.8	duodenum,endometrium,prostate,urinary bladder: 0.2	Not detected		
TACR1	NK1R, NKIR, SPR, TAC1R	ENSG00000115353	Tachykinin receptor 1	2	75046463-75199700	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA074573	Enhanced					Mixed	Tissue enhanced		cervix, uterine: 7.3	fallopian tube: 4.7	Not detected		
TBXA2R		ENSG00000006638	Thromboxane A2 receptor	19	3594506-3606840	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA077366			Supported	Nuclear speckles<br>Plasma membrane	Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable)	Expressed in all	Mixed			spleen: 5.2	Cell line enhanced		HeLa: 6.4;U-2197: 6.3
TBXAS1	CYP5, CYP5A1, THAS, TS, TXAS, TXS	ENSG00000059377	Thromboxane A synthase 1	7	139777051-140020325	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031257, HPA031258, HPA031259	Enhanced		Supported	Vesicles	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Mixed			spleen: 56.3	Cell line enhanced		NB-4: 48.5;PC-3: 22.1;U-937: 48.2
TEK	CD202b, TIE-2, TIE2, VMCM, VMCM1	ENSG00000120156	TEK receptor tyrosine kinase	9	27109141-27230175	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010359, HPA073265	Approved		Supported	Plasma membrane<br>Microtubule organizing center	Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 65.9	lung: 42.6	Group enriched	8	HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
TFPI	EPI, LACI, TFI, TFPI1	ENSG00000003436	Tissue factor pathway inhibitor	2	187464230-187565760	Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA005575, CAB020842	Supported		Approved	Intermediate filaments<br>Cytosol	Cervical cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 267.0	Cell line enhanced		HHSteC: 309.8;HUVEC TERT2: 601.4;LHCN-M2: 367.6;TIME: 354.9
TH	DYT5b	ENSG00000180176	Tyrosine hydroxylase	11	2163929-2171877	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002522, HPA013768, HPA061003, CAB072340	Enhanced	Supported				Tissue enhanced	Tissue enriched	81	adrenal gland: 259.8	adipose tissue: 3.2	Group enriched	26	PC-3: 54.8;SK-BR-3: 15.7
THRA	AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3	ENSG00000126351	Thyroid hormone receptor, alpha	17	40058290-40093867	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009654, CAB023349	Uncertain		Supported	Cytosol	Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 238.9	Expressed in all		
THRB	ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2	ENSG00000151090	Thyroid hormone receptor beta	3	24117160-24495282	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002008, CAB002009, HPA061035	Approved		Supported	Nuclear bodies	Renal cancer:9.46e-8 (favourable)	Mixed	Mixed			cerebral cortex: 36.3	Cell line enhanced		K-562: 43.8;RT4: 28.1
TLR2	CD282, TIL4	ENSG00000137462	Toll like receptor 2	4	153701500-153705699	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA060231, HPA071546			Supported	Nucleus<br>Mitochondria	Renal cancer:1.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 52.7	bone marrow: 34.8	Cell line enhanced		RT4: 8.5;THP-1: 25.3
TLR7		ENSG00000196664	Toll like receptor 7	X	12867083-12890380	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA059613	Enhanced					Mixed	Mixed			placenta: 9.2	Group enriched	5	Daudi: 11.6;U-266/70: 12.4
TLR9	CD289	ENSG00000239732	Toll like receptor 9	3	52221080-52226163	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		lymph node: 3.0	spleen: 2.0	Group enriched	10	Daudi: 23.9;RPMI-8226: 14.8;U-698: 8.8
TNF	DIF, TNF-alpha, TNFA, TNFSF2	ENSG00000232810	Tumor necrosis factor	6	31575567-31578336	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 3.7	lymph node: 1.3	Group enriched	5	HDLM-2: 13.9;HMC-1: 12.0;NB-4: 27.3
TNFRSF8	CD30, D1S166E, KI-1	ENSG00000120949	TNF receptor superfamily member 8	1	12063377-12144207	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000016, HPA032081, HPA032082	Approved					Tissue enriched	Tissue enhanced		appendix: 4.1	adipose tissue: 3.1	Cell line enriched	22	HDLM-2: 528.2
TNFSF11	CD254, ODF, OPGL, RANKL, TRANCE	ENSG00000120659	Tumor necrosis factor superfamily member 11	13	42562736-42608013	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009193, HPA045142	Enhanced					Mixed	Tissue enhanced		lymph node: 17.3	appendix: 6.3	Cell line enhanced		HSkMC: 1.5;NTERA-2: 3.0
TNFSF13B	BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20	ENSG00000102524	Tumor necrosis factor superfamily member 13b	13	108251240-108308484	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009188	Enhanced				Renal cancer:2.53e-11 (unfavourable)	Expressed in all	Mixed			appendix: 35.3	Cell line enriched	9	U-937: 130.0
TNNC1	TNNC	ENSG00000114854	Troponin C1, slow skeletal and cardiac type	3	52451102-52454070	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002450, HPA044848, HPA056897	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Mitochondria		Mixed	Group enriched	16	heart muscle: 4938.6;skeletal muscle: 7104.7	esophagus: 383.0	Cell line enhanced		CACO-2: 53.1;EFO-21: 58.5;HSkMC: 46.0;U-2 OS: 99.1
TOP1		ENSG00000198900	Topoisomerase (DNA) I	20	41028818-41124487	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009058, HPA019039	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.7	Expressed in all		
TOP1MT		ENSG00000184428	Topoisomerase (DNA) I, mitochondrial	8	143304384-143359979	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001915, HPA021542	Approved		Supported	Mitochondria	Renal cancer:1.52e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 41.2	Expressed in all		
TOP2A	TOP2	ENSG00000131747	Topoisomerase (DNA) II alpha	17	40388516-40417950	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002448, HPA006458, HPA026773	Enhanced	Approved	Supported	Nucleus<br>Nucleoli	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 108.5	lymph node: 47.7	Expressed in all		
TOP2B		ENSG00000077097	Topoisomerase (DNA) II beta	3	25597905-25664907	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004601, HPA024120, HPA050441	Supported		Enhanced	Nucleus	Liver cancer:1.86e-7 (unfavourable), Renal cancer:2.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 107.4	Expressed in all		
TPH1	TPH, TPRH	ENSG00000129167	Tryptophan hydroxylase 1	11	18017564-18042426	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010767, HPA022483	Enhanced		Uncertain	Cytosol		Mixed	Group enriched	6	colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5	prostate: 2.4	Mixed		
TPH2	FLJ37295, NTPH	ENSG00000139287	Tryptophan hydroxylase 2	12	71938846-72186618	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046274, CAB078198	Enhanced	Supported				Not detected	Tissue enhanced		cerebral cortex: 1.0	testis: 0.2	Not detected		
TPK1	HTPK1, PP20	ENSG00000196511	Thiamin pyrophosphokinase 1	7	144451941-144836395	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021545, HPA021849	Approved		Approved	Vesicles		Mixed	Mixed			duodenum: 14.4	Cell line enhanced		AN3-CA: 65.0;EFO-21: 19.9
TPMT		ENSG00000137364	Thiopurine S-methyltransferase	6	18128311-18155074	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019851	Approved				Endometrial cancer:8.45e-5 (unfavourable), Renal cancer:1.10e-4 (favourable), Ovarian cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 129.8	Expressed in all		
TPO	TPX	ENSG00000115705	Thyroid peroxidase	2	1374223-1543711	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007987, CAB009587	Enhanced					Tissue enriched	Tissue enriched	103	thyroid gland: 1817.4	spleen: 17.6	Cell line enhanced		Karpas-707: 6.9;RPMI-8226: 2.9
TRHR		ENSG00000174417	Thyrotropin releasing hormone receptor	8	109086621-109119584	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055162	Supported					Not detected	Not detected			thyroid gland: 0.2	Not detected		
TRPA1	ANKTM1	ENSG00000104321	Transient receptor potential cation channel subfamily A member 1	8	72019917-72075617	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Colorectal cancer:6.57e-4 (favourable)	Mixed	Tissue enhanced		urinary bladder: 29.5	gallbladder: 11.4	Cell line enriched	5	HHSteC: 21.8
TRPM8		ENSG00000144481	Transient receptor potential cation channel subfamily M member 8	2	233917398-234019522	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level						Liver cancer:7.15e-4 (favourable)	Tissue enriched	Tissue enriched	8	prostate: 127.3	liver: 16.2	Cell line enhanced		Karpas-707: 3.9;RPTEC TERT1: 6.2;SK-MEL-30: 6.6;WM-115: 5.0
TRPV1	VR1	ENSG00000196689	Transient receptor potential cation channel subfamily V member 1	17	3565444-3609411	FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Not detected	Mixed			duodenum: 7.8	Mixed		
TRPV3	VRL3	ENSG00000167723	Transient receptor potential cation channel subfamily V member 3	17	3510502-3557995	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA069550			Approved	Plasma membrane<br>Centrosome<br>Cytosol		Mixed	Tissue enhanced		skin: 5.1;small intestine: 4.5	duodenum: 1.7	Cell line enhanced		BEWO: 3.6;RH-30: 9.0;T-47d: 3.7
TSHR	LGR3	ENSG00000165409	Thyroid stimulating hormone receptor	14	80954989-81146302	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000473	Approved					Tissue enriched	Tissue enriched	282	thyroid gland: 445.5	lymph node: 1.5	Cell line enhanced		MOLT-4: 18.4;SCLC-21H: 25.2;U-266/70: 7.9
TSPO	BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS	ENSG00000100300	Translocator protein	22	43151514-43163242	Cancer-related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB011232, HPA046260	Uncertain		Approved	Vesicles<br>Mitochondria<br>Cytosol	Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 300.6	Mixed		
TUBA1A	B-ALPHA-1, FLJ25113, TUBA3	ENSG00000167552	Tubulin alpha 1a	12	49184796-49189324	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB008686, HPA039247, HPA043684, HPA063394	Enhanced		Enhanced	Microtubules	Renal cancer:2.90e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 1373.1	Expressed in all		
TUBA4A	FLJ30169, H2-ALPHA, TUBA1	ENSG00000127824	Tubulin alpha 4a	2	219249711-219278170	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004621, CAB005887, HPA039247, HPA043684, HPA063394	Approved		Enhanced	Microtubules	Liver cancer:4.54e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 181.8	Cell line enhanced		HBEC3-KT: 297.7
TUBB	M40, MGC16435, OK/SW-cl.56, Tubb5	ENSG00000196230	Tubulin beta class I	6	30720201-30725426	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005417, CAB012406, HPA043640, HPA046280	Enhanced		Supported	Microtubules	Renal cancer:2.62e-8 (unfavourable), Liver cancer:5.97e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 72.3	Mixed		
TUBB1	dJ543J19.4	ENSG00000101162	Tubulin beta 1 class VI	20	59019254-59026654	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004286, HPA043640, HPA046280	Approved					Not detected	Group enriched	5	bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5	gallbladder: 0.5	Cell line enriched	20	HEL: 24.9
TUBB3	beta-4, CFEOM3, CFEOM3A, FEOM3	ENSG00000258947	Tubulin beta 3 class III	16	89921392-89938761	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Approved					Mixed	Tissue enriched	6	cerebral cortex: 195.6	adrenal gland: 34.5	Cell line enhanced		SCLC-21H: 490.8
TUBB4B	Beta2, TUBB2C	ENSG00000188229	Tubulin beta 4B class IVb	9	137241213-137243707	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010880, HPA043640, HPA046280	Enhanced		Supported	Microtubules	Thyroid cancer:6.36e-6 (favourable), Endometrial cancer:4.91e-4 (favourable), Liver cancer:9.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 786.8	Expressed in all		
TUBD1	FLJ12709, TUBD	ENSG00000108423	Tubulin delta 1	17	59859482-59892945	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004609, HPA023980, HPA027090	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.00e-5 (unfavourable), Colorectal cancer:2.04e-4 (favourable), Renal cancer:6.06e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 12.5	Expressed in all		
TUBE1	dJ142L7.2, FLJ22589, TUBE	ENSG00000074935	Tubulin epsilon 1	6	112070777-112087529	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA032073, HPA032074	Approved					Expressed in all	Expressed in all			testis: 55.3	Expressed in all		
TUBG1	TUBG, TUBGCP1	ENSG00000131462	Tubulin gamma 1	17	42609676-42615234	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004608	Enhanced				Liver cancer:1.08e-8 (unfavourable), Renal cancer:6.48e-5 (unfavourable), Endometrial cancer:8.99e-4 (favourable)	Expressed in all	Tissue enriched	6	testis: 242.8	smooth muscle: 40.2	Expressed in all		
TXNRD1	GRIM-12, Trxr1, TXNR	ENSG00000198431	Thioredoxin reductase 1	12	104215779-104350305	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001395, CAB004607, CAB015834, HPA043871	Approved		Supported	Nucleus	Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 109.1	Expressed in all		
TYMS	HsT422, TMS, TS, Tsase	ENSG00000176890	Thymidylate synthetase	18	657604-673578	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002784	Enhanced				Liver cancer:5.10e-6 (unfavourable)	Expressed in all	Mixed			testis: 59.1	Expressed in all		
TYR	OCA1, OCA1A, OCAIA	ENSG00000077498	Tyrosinase	11	89177452-89295759	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB000079, HPA043241, HPA050889	Enhanced		Enhanced	Vesicles		Tissue enriched	Tissue enriched	33	skin: 29.8	breast: 0.9	Cell line enriched	1211	SK-MEL-30: 256.2
UGCG	GCS	ENSG00000148154	UDP-glucose ceramide glucosyltransferase	9	111896766-111935369	Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024124	Approved				Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 84.1	Expressed in all		
VAMP1	SYB1, VAMP-1	ENSG00000139190	Vesicle associated membrane protein 1	12	6462237-6470987	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002779, CAB016119, CAB079000	Approved	Approved			Renal cancer:1.04e-11 (unfavourable), Colorectal cancer:6.37e-5 (unfavourable), Liver cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 43.5	Cell line enriched	5	U-698: 140.4
VAMP2	SYB2, VAMP-2	ENSG00000220205	Vesicle associated membrane protein 2	17	8159149-8163546	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB078785		Supported			Renal cancer:9.76e-8 (favourable), Pancreatic cancer:3.83e-6 (favourable), Endometrial cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 483.5	Expressed in all		
VDR	NR1I1, PPP1R163	ENSG00000111424	Vitamin D (1,25- dihydroxyvitamin D3) receptor	12	47841537-47943048	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	CAB004617, HPA047740			Enhanced	Nucleoplasm	Renal cancer:4.89e-6 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 175.9	small intestine: 57.9	Cell line enhanced		HDLM-2: 73.7;U-937: 60.2
VEGFA	VEGF, VEGF-A, VPF	ENSG00000112715	Vascular endothelial growth factor A	6	43770184-43786487	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005429, CAB039240, HPA069116, CAB069907	Supported				Renal cancer:1.76e-5 (unfavourable), Liver cancer:2.34e-5 (unfavourable), Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.73e-4 (favourable), Cervical cancer:4.50e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 452.5	Expressed in all		
VEGFB	VEGFL, VRF	ENSG00000173511	Vascular endothelial growth factor B	11	64234538-64238793	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Expressed in all	Expressed in all			adipose tissue: 195.0	Expressed in all		
VKORC1	VKCFD2	ENSG00000167397	Vitamin K epoxide reductase complex subunit 1	16	31090842-31095980	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042720	Approved		Supported	Endoplasmic reticulum	Renal cancer:2.09e-10 (unfavourable)	Expressed in all	Expressed in all			liver: 141.4	Expressed in all		
VKORC1L1		ENSG00000196715	Vitamin K epoxide reductase complex subunit 1 like 1	7	65873267-65959563	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA053954	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			adipose tissue: 57.5	Expressed in all		
VWF	F8VWF	ENSG00000110799	Von Willebrand factor	12	5948874-6124770	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB001694, HPA001815, HPA002082, CAB072874, CAB072875	Supported				Stomach cancer:2.31e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 155.1	lung: 115.9	Cell line enriched	57	HUVEC TERT2: 468.1
XDH	XO, XOR	ENSG00000158125	Xanthine dehydrogenase	2	31334321-31414715	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062641, HPA069323	Supported		Supported	Nucleus	Urothelial cancer:8.73e-6 (favourable)	Mixed	Tissue enhanced		breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6	colon: 11.2	Cell line enhanced		HBEC3-KT: 14.4;hTERT-HME1: 23.9
YES1	c-yes, HsT441, Yes	ENSG00000176105	YES proto-oncogene 1, Src family tyrosine kinase	18	721588-812546	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004370, HPA026480	Approved		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 62.0	Mixed		
